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ELEVATED COCHLEAR ADENOSINE CAUSES HEARING LOSS VIA ADORA2B
SIGNALING
Jeanne Marie Dominique P. Manalo, B.S.
Advisory Professor: Yang Xia, M.D., Ph.D.
Over 538 million people in the world have been diagnosed with hearing loss
(HL). Current treatments for the most common type of HL, sensorineural HL, are
limited to hearing aids and cochlear implants with no FDA-drugs available. The hearing
process demands an abundance of ATP and HL is often attributed to a disruption in this
metabolic energy currency. Patients who lack adenosine deaminase (ADA), the enzyme
that irreversibly metabolizes adenosine, have high levels of adenosine that yield severe
health problems, including HL; however, the pathogenic mechanisms behind HL and
adenosine remain elusive. Our lab has found a HL phenotype in Ada-deficient mice
(Ada -/- ) that parallels ADA-deficient humans. We characterized shifts in both DPOAE
and ABR thresholds in Ada -/- mice with high adenosine levels. Moreover, we found that
these mice have an overall lowered firing capacity of both peripheral and cochlear
nucleus and slow latency transmission between structures. We also observed nerve
fiber density loss and aberrant myelin compaction. More importantly, we found that
treatment of FDA-approved drug, polyethylene glycol-ADA (PEG-ADA), lowered cochlear
adenosine levels and improved functional and structural phenotypes of Ada -/- mice. In addition
to continuous treatment of PEG-ADA in Ada -/- mice, we also rescued these phenotypes
in mice with HL after adenosine accumulation for two weeks. Together, these results
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provide fundamental evidence that elevated cochlear adenosine causes hearing loss via
perturbations of myelin structures.
Interestingly, out of all four adenosine receptors, adenosine a2b (ADORA2B)
was found to have the highest mRNA expression in untreated Ada -/- cochlea. We
observed that genetically and pharmacologically ablating ADORA2B in the Ada -/- mice
attenuated hearing deficiencies and rescued nerve fiber density and myelin compaction
of cochlear nerve. With these findings, we reveal that elevated adenosine-mediated
hearing loss is dependent on ADORA2B signaling that leads to overall hearing
sensitivity decline.
Extending from our Ada-/- mice, we used aged mice as an additional SNHL model. Aging
organs have been associated with hypoxia and, consequently, increased adenosine levels. Indeed,
we found that aged Adora2b-/- rescued hearing sensitivity. Moreover, we used a therapeutic
approach for both models to further validate the role of ADORA2B by using a specificADORA2B antagonist, PSB1115. PSB1115-treated aging mice also have rescued hearing
sensitivity. We also explored another disease model that our lab found to have elevated systemic
adenosine with reported HL in the clinic: sickle-cell disease (SCD). We found that C57B6/J mice
transplanted with SCD mice bone marrow (BM) have hearing loss; however, we found that
Adora2b-/- mice with SCD BM have attenuated hearing loss. Overall, our study supports the
clinical and existing research on the relationship between adenosine signaling and hearing loss.
Understanding this purinergic signaling establishes a strong foundation for molecular-based
therapy in a very common disability.
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CHAPTER 1: Background and Significance
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1.1 Introduction
Hearing loss (HL) affects millions of people worldwide resulting in an annual global cost
of over $700 billion (1). HL impacts effective communication with others, loss of cognitive
function, and can lead to depression (2). Current treatments for the most common type of HL,
sensorineural HL (SNHL), are limited to hearing aids and cochlear implants, with no FDAapproved drugs available. Multiple conditions are known to cause HL including genetic, drug,
aging and noise. It is commonly accepted that the hearing process demands an abundance of ATP
and that HL is often attributed to a disturbance in this metabolic energy currency (3–9). Thus, it
is imperative to investigate the metabolic and molecular basis underlying HL, a leading public
health concern, and establish novel approaches to treat and prevent its progression.
Adenosine functions as a signaling nucleoside that orchestrates a physiological and
pathological response to energy deficiency or cell injury by the activation of one or more of the
four adenosine receptors (10) . Under hypoxia, energy insufficiency, and cellular damage, ATP
is released from cells, which can then be hydrolyzed into AMP and further into adenosine by two
ectonucleotidases, CD39 and CD73. Extracellular adenosine is eliminated by the uptake into cells
by of equilibrative nucleotide transporters (ENTs). Intracellular adenosine is irreversibly
degraded by adenosine deaminase (ADA), leading to increased uptake of extracellular adenosine
by ENT2. However, extracellular adenosine concentrations can reach as high as 100 µM under
stress (9). Adenosine signaling activates four adenosine receptors (ADORA-1, -2A, -2B, and -3.)
that are found present in rodent cochlea (11). These receptors fulfill different roles due to their
variable distribution of expression in different cell types and according to the level of adenosine
present (9).
Presbycusis, age-related hearing loss, is the most common type of SNHL. Age-related
cochlear pathogenesis has been posited to be due to increased levels of ROS, perturbed blood
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flow, and persistent noise-exposure (12–14). Previous studies have shown that acousticoverstimulation result in increased ATP release in the cochlear partition (3,15,16). Although the
effects of sustained levels of cochlear adenosine have yet to be determined, studies have shown
that various organs have elevated adenosine during the aging process, especially the auditory
cortex (17–24). Early studies showed that adenosine signaling is involved in multiple animal
models of HL. For example, ADORA-1 and -3 have a protective role in noise-induced and
cisplatin-induced models of HL by regulating antioxidant production and presynaptic glutamate
release among other functions (9). ADORA2A, on the other hand, is mainly expressed in the
organ of Corti, spiral ganglion neurons (SGN), and cochlear vasculature and may play a
detrimental role in HL by persistent vasodilation (9,25). Among four adenosine receptors,
ADORA2B has the least affinity for adenosine and is, therefore, only activated by chronically
elevated levels of adenosine. Early studies showed that excess adenosine signaling via
ADORA2B leads to multiple cellular damage, dysfunction and disease progression including
chronic kidney disease, sickle cell disease, priapism and preeclampsia (26–32). However, the
functional role of ADORA2B signaling in SNHL remains unknown.
Patients with ADA-deficiency have chronically elevated levels of circulating adenosine
that result in severe health problems including immunodeficiency (7) . Unexpectedly, ADAdeficient patients developed bilateral SNHL (7,33,34). Deafness and SNHL in ADA-deficient
patients were not ascribed to any genetic-, structural-, drug-, or infection-affiliated cause,
implicating a metabolic disturbance related to elevated adenosine (7). Consistently, recent studies
validated that ADA-deficient mice (Ada-/-) mimicking ADA-deficient humans display the
phenotype of HL and that polyethylene glycol-ADA (PEG-ADA) treated 7-day post-partum Ada/-

mice have improved hearing and immune abnormalities (35). Thus, elevated cochlear adenosine

is likely a common metabolic signaling molecule involved in SNHL in ADA-deficiency and other
conditions such as aging, noise and drugs.

To define the pathogenic mechanism of elevated
3

cochlear adenosine in SNHL, we took advantage of adult Ada-/- mice and aged wild type (WT)
mice, two distinct animal models with SNHL, to probe cellular, molecular and metabolic basis
underlying elevated cochlear adenosine in SNHL with a goal to develop innovative therapies.
Here we report that ADORA2B-mediated impairment of myelination of SGN is a common
pathogenic mechanism underlying SNHL in both Ada-/- mice and aged WT mice, establishing a
strong foundation for adenosine-based therapy in SNHL, a very common disability.
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1.2 Hearing Process

SOUND INPUT

MECHANICAL TRANSDUCTION
Organ of Corti

Ossicles

TM

TM

Ear
Canal

ELECTRICAL TRANSDUCTION

OHC
cochlea

SGN
NF

IHC

basilar membrane

HEARING
PROCESS
IN HIGHER
BRAIN
REGIONS

HEARING PROCESS

Figure 1. Overview of the Hearing Process
Schematic diagram of the hearing process starting from the sound input into the external ear that
vibrates the middle ear ossicles, followed by stimulation of the inner ear sensory cells found in
the cochlea. Hair cell movement of outer and inner hair cells (OHC, IHC) releases
neurotransmitters onto the bipolar spiral ganglion neurons (SGN) that communicate with higher
brain regions.
Function and Structure of the Auditory Pathway

The hearing process requires a sophisticated orchestration of multiple structures and cell
types. This involves the external ear, middle ear, and inner ear that produce consecutive
mechanical and electrical transduction upon sound stimulation. Sound is a wave from a vibrating
object that propagates pressure variation through air (36). Thus, when sound waves reach the ear,
it creates a vibration that sets hearing into motion through the ear drums.

The external ear is responsible for capturing sound from surroundings through the pinna.
Sound travels through the ear canal, which begins the transfer of sound waves from air into a
denser medium, the tympanic membrane (Figure 1). This is the beginning of the mechanical
transduction of the hearing process.
5

The tympanic membrane, then, transmits this vibration into the ossicles in the middle ear.
This causes the oval window of the inner ear to also vibrate, leading to the motion of inner ear
fluid. The inner ear is comprised of the vestibular system and the cochlea, responsible for sensing
balance and equilibrium, as well as hearing, respectively.

The cochlea contains fluid compartments: perilymph that is found in scala tympani, and
scala vestibuli and endolymph found in the scala media. Vibrations in the scala media are the
impetus of electrical stimulation in the hearing process. The mechanoelectrical transition occurs
in the Organ of Corti, which includes the inner and outer hair cells sitting on the basilar membrane
that spans from the base to the apex of the cochlea. These hair cells have hair bundles, composed
of stereocilia, on its apical surface that are “sheared” by the tectoral membrane (TM) upon
vibration of Organ of Corti and basilar membrane (Figure 1).

The mechanical shearing of hair cells causes depolarization, consequently releasing
neurotransmitters to stimulate cochlear nerve fibers. Depolarization of hair cells sends signals to
bipolar first order neurons (spiral ganglion cells) that synapse to the cochlear nucleus. Activation
of cochlear nucleus is processed into the higher regions of the central auditory pathways.

1.3 Hearing Loss and Adenosine Signaling
Clinical Significance
According to the World Health Organization (WHO), hearing loss affects around 466
million people worldwide. WHO also predicts that this number will rise to almost a billion by
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2050 (1). HL impacts effective communication with others, loss of cognitive function, and can
lead to depression (2). There are several types of HL, however, the most commonly reported is
sensorineural HL (SNHL). Patients with SNHL have damaged cochlea and auditory nerve where
the hair cells and spiral ganglion neurons (SGN) are non-regenerative. Currently, SNHL patients
are limited to hearing aids and cochlear implants with no pharmacological therapeutic options
(37).
Noise exposure and age-related hearing loss, or presbycusis, are the most common causes
of SNHL in adults. Noise exposure can damage hair cells that are more sensitive to high frequency
at the base of the cochlea. Patients with presbycusis, on the other hand, may still be sensitive to
low-frequency sounds, but have difficulty distinguishing high-frequency sounds that can affect
spoken communication. This loss of sensitivity to high-frequency sounds usually has nerve cell
and stria vascularis damage and can progressively worsen to deterioration of low and middlefrequency hearing over time.
Current Findings in Adenosine Signaling & Hearing
Elevated extracellular adenosine is an important signaling molecula involved in
pathological conditions. Cells under stress release high levels of ATP extracellularly which are
consequently hydrolyzed into ADP and adenosine by ectonucleotidases. Adenosine is then
irreversibly metabolized into inosine by adenosine deaminase (ADA), or is uptake by nucleoside
transporters intracellularly for further breakdown into inosine or AMP by ADA and adenosine
kinase (ADK), respectively. As many studies have shown, tissues under stress can induce a
persistent release of ATP and accumulation of adenosine that result in a deleterious pathogenic
cycle.
Age-related hearing loss (ARHL), presbycusis, is a type of SNHL that has been attributed
to a variety of causes. ARHL occurs with more frequency with people increasing in age, such as
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other age-related disease like atherosclerosis, cancer, cardiovascular disease, and so on (38).
Aging is the naturally occurring gradual decline of organ function orchestrated by damaging
biological processes overtime; however, the exact molecular mechanisms that underlie ARHL
remain to be elucidated. Persistent noise trauma can accelerate presbycusis and studies have
shown that acoustic-overstimulation can result in increased ATP in cochlear fluid (3,15,16).
Additionally, age-related diseases like atherosclerosis and diabetes can perturb blood flow and
supply in the cochlea, respectively (39). One study showed that pharmacological inhibition of
ADK prevented ARHL in mice and postulated that increased cochlear endogenous adenosine
levels preserves sensorineural functions in low-frequency, apical region (40). Overall, preserving
cells in aging cochlea; however, this study did not evaluate how the direct changes in adenosine
levels affect hearing. The manipulation of cochlear adenosine levels during the aging process has
never been investigated. However, previous studies have shown an increase in adenosine levels
in aging organs (17,18,20–24). Particularly, the thalamus and auditory cortex where adenosine
has been shown to play a role in auditory plasticity in the CNS (19). This study points out how
adenosine levels play an important role in hearing.
SNHL was reported in humans lacking adenosine deaminase (ADA), an enzyme that
irreversibly metabolizes adenosine into inosine (7,33,34). HL in these patients was not attributed
to genetic, drug, infection, or treatment-related causes; therefore HL in these patients is implicated
to be a metabolic disturbance due to elevated systemic adenosine levels (7). In 2019, a study
showed for the first time how ADA-deficient mice (Ada-/-) parallel ADA-deficient humans by
having bilateral HL (35). They also showed how enzyme replacement therapy with polyethylene
glycol-ADA (PEG-ADA) can improve hearing and immune pathologies in young developing
mice (35). However, the exact pathogenic mechanisms of elevated adenosine levels in HL still
remain elusive.
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Future objectives in hearing loss research should determine the molecular basis of how
elevated adenosine results in HL to develop effective treatment and preventative therapeutic
options. Fulfilling these objectives will not only broaden our understanding of adenosine signaling
in inner ear physiology and help treat a very common disability. The impact of the proposed
research alleviates both patient suffering and overall economic burden of billions of dollars
dedicated to HL health sectors and educational support systems (41).
1.4 ADORA2B Signaling
ADORA1, ADORA2A, and ADORA3 in Hearing Loss
Adenosine receptors are G-protein coupled-receptors that induce a variety of intracellular
signaling pathways, depending on whether they stimulate or inhibit adenylyl cyclase. Adenosine
receptor 1 (ADORA1) and adenosine receptor 3 (ADORA3) both inhibit adenylyl cyclase by
coupling to Gi/o. proteins. Adenosine 2a and adenosine 2b receptors, on the other hand, stimulate
adenylyl cyclase via (9)Gs or Golf proteins. Several studies in the hearing field have investigated
the roles of ADORA1, -2A, and 3, exemplifying their different roles through activating various
downstream pathways with evidence dependent on varying adenosine levels.
All four adenosine receptors have different affinities for adenosine, with ADORA1 having
the highest. ADORA1 stimulation has been found to generally be protective in noise- and druginduced HL (4,42–44). ADORA1 is posited to have a cytoprotective role under cochlear stress
through inhibiting glutamate excitotoxicity by inhibiting glutamate release, a known ADORA1
function in the central nervous system (4). Another hypothesis is the idea that ADORA1 may be
reducing oxidative stress and reduce apoptotic effects during cochlear acoustic trauma, overall
protecting hair cells (8).
ADORA2A has the highest affinity for adenosine next to ADORA1. ADORA2A has been
the major adenosine receptor for modulating inflammation. In hearing research, however,
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previous studies show that whole genetic deletion of ADORA2A in mouse exposed to noise
preserved outer hair cells ribbon synapses, and spiral ganglion neurons, which may indicate while
both ADORA2A and ADORA1 play a role in apoptosis, they may have differing regulatory
functions (45).
ADORA3 stimulation has varying effects in the cochlea that are dependent on agonist
dosage. Previous studies have shown that lower dosages of ADORA3 agonists may induce
pathways that promote tissue survival, but may promote apoptosis at higher dosages (9,46,47).
Overall, little is known about ADORA3 functionality in the hearing field and needs to be
investigated further.
All three high-affinity adenosine receptors have been investigated in the hearing field.
While these receptors have been studied in rodents, a molecular function gleaned from these
studies remain a mystery. Additionally, identifying each receptor’s role and how they orchestrate
downstream pathways in response to different levels of extracellular adenosine remains to be
investigated.

ADORA2B signaling may play a role in hearing

While all four receptors are found to be expressed in rodent cochlea, ADORA2B is the
remaining receptor yet to be investigated in the hearing field. ADORA2B receptor has the least
affinity among the four adenosine receptors. ADORA2B’s activation is dependent on excessive
and chronic extracellular adenosine presence and is known to induce downstream pathological
pathways, such as sickle cell disease, chronic kidney disease, and priapism and preeclampsia (26–
32). Although ADORA2B has not been studied in the hearing process, it has been posited that
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activation of this receptor can activate JNK, where inhibition of JNK has been found to protect
acoustic trauma and cytotoxic antibiotics through hair cell survival (48,49).
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CHAPTER 2: Elevated Cochlear Adenosine and Hearing Loss
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2.1 Introduction
As previously mentioned in Chapter 1, the exact molecular mechanism of how elevated
adenosine causes hearing loss remains to be studied. To address this, we used Ada-/- deficient
mice and PEG-ADA enzyme replacement therapy to study how manipulations in systemic
adenosine levels can affect hearing. In this chapter, we show how cochlear elevated adenosine
affects hearing sensitivity and sensory cells in the cochlear. More importantly, we also show
whether resumption of PEG-ADA in Ada-/- mice with hearing loss caused by elevated adenosine
can rescue pathological phenotypes.
2.3 Materials & Methods
Ada-/- Mice
Ada-/- mice were generated and genotyped as previously reported (50). Mice homozygous
for the null Ada allele were labeled Ada-/-, while mice genotyped with the Ada allele were labeled
as Adawt. All mice were congenic on a C57BL/6 background, and all phenotypic comparisons
were performed among littermates.

PEG-ADA generation and regimen
Polyethylene glycol-modified-ADA (PEG-ADA) was produced from purified bovine
ADA with activated PEG previously described (51–53). Ada mice were injected 15 ul
intramuscularly from birth to postpartum day 18 every 4 days. Mice older than postpartum day
18 were injected once a week with 100 ul of diluted PEG-ADA (1:5 with 1x sterile DPBS)
intraperitoneal injections until they reach 8 weeks of age. PEG-ADA treated group were given
this treatment continuously from 8-10 weeks of age, while STOP-treatment group were deprived
of drug within these two weeks. RESCUE group had PEG-ADA withdrawn for two weeks at 8
13

weeks followed by PEG-ADA resumption of intraperitoneal injections every other day for one
week.
Hair Cell Loss and Cochleograms
Cochleae were prepared and evaluated as previously described (54,55).

The

anesthetized mice were decapitated and their bullae was quickly removed and opened to expose
the inner ear. Afterward, the cochleae were immersed in 10% formalin fixative and shipped to
University of Buffalo for analysis. Cochleae were stained with Ehrlich’s hematoxylin solution,
the organ of Corti carefully microdissected out into two or three segments and mounted as a flat
surface preparation in glycerin on glass slides (54). Surface preparations were examined with a
light microscope (Zeiss Standard, 400X magnification). Surface preparations were photographed
with a digital camera (SPOT Insight, Diagnostic Instruments Inc), processed with imaging
software (SPOT Software, version 4.6) and images assembled with Adobe Photoshop 5.5. Inner
hair cells (IHC) and outer hair cells (OHC) were counted along successive 0.12-0.24 mm intervals
of the organ of Corti beginning at the apex. Hair cells were counted as present if the cell body
and cuticular plate were intact. Cochleograms showing percent hair cells missing as a function
of percent total distance from the apex were constructed for each animal. Percent hair cell losses
were based on laboratory norms for young CBA mice (54).
Cochlea EM
Cochlea was fixed in 2% buffered glutaraldehyde, followed by decalcifcation with a
formic acid/formalin solution (1M formaldehyde, 2.5M formic acid, pH 2.0). Fixed cochlea was
dehydrated and was embedded in plastic via an automated tissue processor for electron
microscopic specimens. Embedded tissues were sectioned at 0.6 micrometers. The tissue sections
were stained with uranyl acetate and lead citrate. The tissue was examined using a transmission
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electron microscope and digital images were obtained. G-Ratio analyses was adapted from Gratio
ImageJ plug-in (http://gratio.efil.de/download/).
Cochlea isolation, immunohistochemistry, imaging, and analysis
Temporal bones were dissected in PBS, incubated in 4% paraformaldehyde (PFA) in PBS
overnight at 4°C, decalcified in 0.2 M EDTA for 5–7 d. Fixed tissue was embedded in OCT
compound, cryosectioned at 10 um, followed by standard immunohistochemistry procedure. The
tissue sections were washed with 1x phosphate-buffered saline (PBS), followed by a 1 hr
incubation in 5% BSA with 1% Triton X-100 in 1xPBS. These sections were then incubated in
primary antibodies overnight at 4°C. The primary antibodies used for this study were: nerve fiber
filament (mouse anti-NF-200, Sigma, 1:200), neuron cell bodies (rabbit anti-NeuN, Abcam,
1:500), and myelin protein zero (rabbit anti-MPZ, Abcam 1:200). Tissues were then incubated
with incubated with appropriate Alexa-Fluor conjugated secondary antibodies (Invitrogen,
1:500), followed by DAPI mountant (ProLong Gold Antifade, Thermo Fisher Scientific).
Confocal z-stacks of each cochlea were taken using Zeiss LSM T-PMT microscope
equipped with 63x (2x digital zoom) oil immersion lens. MPZ- and NF-200 areas were quantified
using ImageJ by selecting via consistent color threshold for each antibody used across all
experiment groups (n=3 each) and normalizing each sample by total area of the axon. These
MPZ+/total axon area and NF200+/total axon quantifications were collectively compared across
all experiments via a Mann-Whitney nonparametric two-tailed t-test. All statistical analyses were
performed via Prism 8.

Auditory brainstem response recording
Mice were intraperitoneally injected with ketamine-xylazine (100 mg/kg: 10mg/kg).
Testing was performed in a soundproof faraday cage booth while mice were placed on heating
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pad to maintain normal body temperature throughout the procedure. Pure tone bursts (0.1 ms
rise/fall, 2 ms duration, 21 presentations/s) from 4 to 48 kHz were generated using System 3
digital signal processing hardware and software (Tucker Davis Technologies). The intensity of
the tone stimuli was calibrated using a type 4938 one-quarter inch pressure-field calibration
microphone (Bru¨el & Kjær). EC1 ultrasonic, low-distortion electrostatic speakers were coupled
to the ear canal to deliver stimuli within 3 mm of the tympanic membrane. Response signals were
recorded with subcutaneous needle electrodes inserted at the vertex of the scalp (channel 1), the
postauricular bulla region (reference), and the back leg (ground), and averaged over 500
presentations of the tone bursts (56). Electrode-recorded activity was filtered (high pass, 300 Hz;
low pass, 3kHz; notch, 60Hz) before averaging to minimize background noise. Auditory
thresholds were determined by decreasing the sound intensity of each stimulus to 10 dB from 90
dB in 5 dB steps until the lowest sound intensity with reproducible and recognizable waveforms
was detected. Thresholds were determined to within 5 dB for each frequency by two raters to
ensure reliability. SD (dB SPL) were plotted as a function of stimulus frequency (kilohertz) and
analyzed for group differences by a two-way ANOVA, followed by a multiple-comparison test,
to reveal overall trends. Prism 8 was used for all statistical analyses.

ABR waveform detection and calculation
Peak amplitudes (I and II) were visually determined from ABR waves detected from each
stimulus from 90 to 10 dB in 5 dB increments at each frequency. Peak amplitudes were measured
by subtracting the peak voltage from the trough voltage at every dB presentation, averaged per
experimental group. All averaged peak amplitudes for each peak from each group were
statistically compared using two-way ANOVA, followed by a multiple comparison test.
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Peak latencies from peak I and II were calculated by subtracting Peak I’s peak amplitude temporal
onset (in ms) from Peak II’s peak amplitude temporal time onset (in ms). Time measurements
were averaged per experimental group. Averaged latencies per group were compared via two-way
ANOVA, followed by a multiple comparison test.
All statistical analyses were performed through Prism 8.

Distortion product otoacoustic emission measurements
DPOAEs were measured from a probe tip microphone placed in the external canal of the
mouse ear that were elicited by two 1-second sine-wave tones of varying frequencies
(F2=1.2*F1). F2 had a varied range of frequencies from 4 to 90 kHz. These two tones were
presented in identical intensities that ranged from 15 to 75 dB Sound Pressure Level (SPL) in 15
dB increments. The magnitude of the 2*F1-F2 DP was determined by FFT. DPOAE thresholds
(>-5 dB SPL and greater than two std. dev above noise floor) were analyzed off-line via BioSigRZ
program. If no DPOAE was detected, we defined the threshold to be at 75 dB, as our equipment
is limited to 80 dB SPL. DPOAE thresholds were averaged per experimental group and compared
via one-way ANOVA, followed by a multiple comparisons test. All statistical analyses were done
through Prism 8.

2.3 Results
Elevated Cochlear Adenosine and Hearing Loss
To determine the pathogenic mechanisms of HL mediated by chronically elevated
adenosine as seen in ADA-deficient humans, we took advantage of using Ada-/- mice, which
manifest most of the phenotypes observed in ADA-deficient humans including HL
(26,27,31,52,57). Although ADA-deficiency is a lethal condition for humans and mice, ADA17

deficient humans and mice can survive indefinitely by enzyme replacement therapy that involves
weekly injection of polyethylene glycol-ADA (PEG-ADA), an FDA-approved drug to reduce
excessive levels of adenosine in ADA-deficient humans and mice(50).

Furthermore, the

experimental ease with which adenosine levels can be regulated by administration of PEG-ADA
represents a powerful investigative strategy (50). Thus, we used PEG-ADA enzyme therapy as a
powerful experimental approach to determine how elevated adenosine contributes to HL in Ada/-

mice. Specifically, Ada-/- mice were maintained on a high dose regimen of PEG-ADA treatment

(5U/wk) from birth to 8wks of age to allow normal neuro-physiological development, including
the auditory system. At 8-weeks of age a control group of Ada-/- mice continued to be treated
with PEG-ADA (PEG-ADA treated Ada-/-). A second group was deprived of PEG-ADA therapy
for 2 weeks to allow adenosine to accumulate, named STOP treatment Ada-/- (Figure 2).

Figure 2. PEG-ADA therapy in Ada-/- mice. Ada-/- mice are treated with PEG-ADA from birth to
8 weeks for normal development. For two weeks, PEG-ADA-treated mice are continually treated
with the drug, while STOP-treatment mice are withdrawn from the drug.

We used HPLC to validate that the Ada-/- mice following 2 week-withdrawal of the PEGADA treatment contained significantly elevated cochlear adenosine levels compared to Ada-/mice with continuous PEG-ADA treatment (Figure 3, left). However, continuous treatment of
18

ADA-/- mice with PEG-ADA did not completely eliminate elevated cochlear adenosine levels to
that observed in WT mice (Figure 3, left).

Next, we tested auditory function in these mice by measuring the auditory brainstem
response (ABR). Consistent to elevated adenosine in Ada-/- mice subjected to PEG-ADA
withdrawn for 2 weeks, these mice displayed significant HL across a wide frequency range (4kHz
to 32kHz) (Figure 3, right), corresponding to a mild to severe HL on a clinical scale that is
consistent with HL reported in ADA-deficient patients(33,34). Significantly, continuous
treatment with PEG-ADA substantially prevented HL in Ada-/- mice (Figure 3, right). Supporting
our observation that Ada-/- mice maintained on continuous PEG-ADA treatment regimen mice
contained slightly higher cochlear adenosine levels than those of WT mice (Figure.3, left), these
mice displayed very mild sensorineural HL (SNHL) compared to the WT mice (Figure 3, right).
Altogether, using Ada-/- mice as a genetic tool coupled with PEG-ADA enzyme therapy to control
cochlear adenosine levels, we provide solid genetic evidence that increased cochlear adenosine
promoted HL in Ada-/- mice and that PEG-ADA treatment lowered adenosine and prevented HL
in these mice.
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Figure 3. Elevated adenosine contributes to hearing loss sensitivity. (left) (mean ± SEM)
Adenosine levels are elevated in STOP-treatment mice compared to all other cohorts (p-value of
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STOP-treatment and PEG-ADA, 0.0017) (n=4 for each condition). (right) (mean ± SEM) After
two-week PEG-ADA withdrawal, auditory brainstem response (ABR) thresholds at different
frequencies demonstrate hearing loss in STOP-treatment mice (p-value of STOP-treatment and
PEG-ADA at 8 and 16 kHz, <0.0001 and 0.0009, respectively) (n=6 for each cohort).

Adenosine and Distortion Product Otoacoustic Emissions
Upon onset of sound stimulation, normal hearing requires a proper mechanical
transduction reflecting the function of overall cochlear amplifier and stimulation of the outer hair
cells (OHC) and electrical transduction reflecting the number of spiral ganglion neurons (SGN)
firing and the speed of transmission from hair cells, spiral ganglion neurons (SGNs) and cochlear
nucleus (CN) in the auditory pathway leading to the brainstem (Figure 1). Thus, to define the
specific impairment from mechanical to electrical transduction underlying HL in Ada-/- mice, we
assessed mechanical transduction measured by the frequency-specific distortion product
otoacoustic emission (DPOAE) analysis (Figure 4) and electrical transduction by measuring I and
II peak amplitude (Figure 5) and inter-peak latency (Figure 6), respectively, in the auditory
pathway leading to the brainstem.
Because hearing for mice is most sensitive at 8 and 16 kHz, we analyzed at these
frequencies. STOP-treatment Ada-/- displayed an increase of DOPAE threshold compared to PEGADA treated Ada-/- mice at 8 kHz (Figure 4, left). A slight increase was also seen at 16 kHz, but
the increase did not achieve significance (Figure 4, right). Overall these results indicate that
elevated cochlear adenosine causes a mild defect in mechanical transduction from sound
stimulation to firing of hair cells.
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Figure 4. Elevated adenosine causes outer hair cell dysfunction at low frequencies. (mean ± SEM)
Distortion-product otoacoustic emissions (DPOAEs) measured at 8 and 16 kHz demonstrate mild
cochlear dysfunction in STOP treatment mice (p-value for 8 and 16 kHz, 0.0150 and 0.1334,
respectively) (n=6 for each cohort).

Adenosine and SGNàCN Amplitude Peaks & Latency
In contrast to the mild decreased in DOPAE, averaged peak amplitudes of STOP-treatment
Ada-/- was significantly lower compared to PEG-ADA treated Ada-/- at 8 and 16 kHz. (Figure 5).
Additionally, extracted SGNàCN peak I to peak II latency was significantly longer in STOPtreatment Ada-/- mice compared to Ada-/- mice with continuous PEG-ADA therapy (Figure 6).
Thus, elevated cochlear adenosine contributes to NSHL in Ada-/- mice via dual mechanisms: 1) a
mild defect in mechanical transduction in the cochlear amplifier and outer hair cells; 2) a much
more severe impairment of electrical transduction featured with the decreased firing of SGNs and
transduction from SGNs to the CN.
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Figure 5. Elevated cochlear adenosine decreases amplitudes of peripheral nerve and cochlear
nucleus. Auditory brainstem response traces were analyzed, where Peak 1 (peripheral nerve)
amplitudes were elevated in PEG-ADA treated mice compared to STOP-treatment mice. Peak II
pertains to cochlear nucleus, showing the same elevation as Peak I, indicating higher capacity of
neurons to fire effectively with lowered adenosine. (p-value for 8 kHz for peak I for 90-75 dB,
<0.0001) (p-value for 8 kHz for peak II 90-75 dB, 0.03096, 0.00623, 0.01439, 0.01468
respectively) (p-value for 8 kHz for peak I and II for 90-75 dB, 0.02534, 0.02643, 0.11141,
0.04031, respectively) (p-value for 16 kHz for peak I and II for 90-75 dB, 0.0323, 0.0352, 0.0207,
0.0396, respectively) (n=6 for each group)
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Elevated Adenosine and Hair cell Structures
Extending from functional understanding of pathogenic mechanism of SNHL in Ada-/mice, we probed the specific cellular changes in Ada-/- mice through diverse histological and
microscopic analyses. First, to determined how the spatial organization of hair cells from the base
to the apex pertain to regions of sensitivity to resonant frequency, we prepared surface preparation
of the entire organ of Corti (Figure 7, left) of PEG-ADA treated and STOP treatment mice and
used them to prepare cochleogram showing the percent OHC and IHC loss as function of percent
distance from the cochlea. Based on the nature of traveling waves moving through the basilar
membrane, outer hair cells, depending on their distance from the apex of the cochlea, are more
sensitive to certain hearing frequencies (Figure 7, right) (58). In STOP-treatment Ada-/- mice, the
OHC (OHC row 1,2,3) losses declined from 100% at the extreme base to less than 10% loss at
the 70% location, indicative of a hair cell functional loss around 48 kHz. OHC losses in PEG23

treated mice were similar, but were restricted to slightly more basal regions. However, we did not
observe any ABR differences between the two groups at 48 kHz. However, we did not observe
any ABR difference at 48 kHz. Thus, a 30% hair cell loss at the base of the cochlea did not cause
functional defect in ABR (Figure 3, right) (59). We also observed 10% loss closer to the apex
where it is sensitive to the lower frequencies, reflecting our DPOAE analysis showing a mild
increase of auditory threshold at 8kHz (Figure 4, left)
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Figure 7. Cochleogram of PEG-ADA treated and untreated Ada-/- and schematic diagram of
tonotopic frequency mapping in inner ear. (left) Representative pictomicrograph of uncoiled
cochlea of B) Ada-/- STOP-treatment mice and A) PEG-ADA treated mice. STOP-treatment mice
demonstrate more outer hair cell loss. (right) Schematic illustration representing the tonotopic
mapping of frequency sensitivities with percent distance plotted from the apex of cochlea.
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Figure 8. Cochleogram analysis comparing hair cell loss of

STOP treatment

treatment mice compared to treated mice. This location

PEG-ADA treated and untreated Ada-/- mice. Cochleogram
from Ada-/- STOP-treatment mice and PEG-ADA treated
mice. Note ~30% loss at cochlear basal turn in STOP-

corresponds to >48 kHz in mice. Data are shown as mean ±
SEM

Elevated Adenosine and Axon Structures
Our ABR assays showed the robust decrease in hearing sensitivity thresholds, wave peak
I and II amplitudes, and prolonged inter-peak latencies in STOP-treatment Ada-/- compared to
PEG-ADA treated Ada-/-, implicating the potential cellular impairment of SGN. To define the
cellular changes of SGNs, we conducted Hematoxylin Eosin (H&E) histological studies to
investigate the cellular changes in SGN. SGNs are grouped bipolar neuron cell bodies with
synaptic dendrites that receive glutamate neurotransmitters released from the base of hair cells.
We found significant cochlear nerve density loss via H&E staining in STOP-treatment Ada-/compared to PEG-ADA treated Ada-/- (Figure. 9D, left panel). Changes in cochlear nerve density
motivated us to closely examine the axonal structures by electron microscopy (EM). Supporting
the finding in H&E, we found a significant increase in unmyelinated axons in STOP-treatment
mice, as well as features of non-compact myelin (Figure. 9, middle and top right). Additionally,
we found a significant increase in G-ratio, which is the ratio of the inner axonal diameter to the
total axonal diameter, indicating the thinning of myelin sheaths in STOP-treatment Ada-/- mice
(Figure. 9, bottom right). Both H&E and EM findings support our conclusion that elevated
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cochlea adenosine impaired myelination of nerve fiber of SGNs without obvious changes of cell
body of SGN.
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Figure 9. Nerve structure in Ada-/- mice cochlea with and without PEG-ADA therapy. (left) High
power magnification of the spiral ganglion (SG) cell bodies in Rosenthal’s canal and myelinated
nerve fibers (NF) in the modiolus. Note dark blue staining of the myelin on the NF in PEG-ADA
treated mice and absence of NF staining and loss of NF in ADA mice where treatment was
discontinued. There seem to be many vacuoles and open spaces in the STOP-treatment group.
(middle) Representative image of electron microscopy of transverse nerve fibers. Yellow stars
indicate loosely compacted myelin (middle) (mean ± SEM) Quantification of unmyelinated fibers
between STOP-treatment and PEG-ADA mice (p-value, 0.0286) (right) (mean ± SEM)
Quantification of G-ratio from EM images, indicating the decrease in thickness in myelin sheaths
in STOP treatment mice (p-value, 0.0229).

Adenosine and Myelin Structures
Myelination in cochlear nerves is responsible for efficient transmission of sound-evoked
spike responses. Therefore, we verified whether the nerve fibers that contact the hair cells directly
26

had changes in pro-myelinating protein responsible for myelin compaction, myelin protein zero
(MPZ) (60–62). MPZ gene dosage is regulated and over expression of MPZ leads to inappropriate
trafficking of the protein between the Schwann cell membranes, leading to a lack of myelin
compaction (63,64). Surprisingly, we observed that STOP treatment Ada-/- mice have significantly
elevated MPZ expression levels without the normal tubular expression found in PEG-ADA treated
Ada-/- mice in compared to treated Ada-/- mice (Figure 10). Consistent to the H&E findings, nerve
fiber stained by NF-200 was significantly reduced (Figure 10). Overall, using H&E, EM and IF
multidisciplinary microscopic approaches, we demonstrated that elevated cochlear adenosine
causes SNHL largely due to the impaired myelination of nerve fiber of SGN, particularly the
myelin sheaths mediated by MPZ integration, and loss of nerve fiber.
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Figure 10. Labeling of nerve fiber and MPZ protein on cochlear nerve. Immunofluorescent
staining of nerve fibers with myelin protein zero (MPZ) where STOP-treatment group have a
more intense expression (p-value <0.0001). Data are shown as mean ± SEM.
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ADA Enzyme Therapy Resumption Rescue
Following withdrawal of PEG-ADA therapy for 2 weeks, Ada-/- mice develop the
profound demyelination of nerve fiber of SGN with impaired integration of MPZ to myelin sheath.
These findings prompted us to assess an important therapeutic possibility whether the elevated
adenosine-induced SNHL is reversible. If so, we questioned how quickly and to what extent
hearing thresholds recover, and if cellular disturbances in SGN would be corrected with PEGADA treatment. To address these questions, we first to determine when the SNHL developed
within the period of PEG-ADA withdrawal over 2-weeks. PEG-ADA’s half-life is 4 days upon
PEG-ADA withdrawal and elevated plasma adenosine reached the peak around day 8 (31). Thus,
within 2-weeks withdrawal of PEG-ADA, we found that the ABR threshold began to increase
around day 4, peaked on day 7 and maintained its peak threshold up to day 14 (Figure 11). Based
on this finding, we chose to resume treatment with 5U/week of PEG-ADA at the end of 2-week
withdrawal of PEG-ADA for one-week treatment (Figure 12). Following resumption of PEGADA therapy, auditory function was monitored using ABR and DPOAE every 4 days until no
further changes are observed (Figure 13).
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response (ABR) thresholds at different frequencies demonstrate a rescued hearing phenotype (pvalue for STOP treatment vs PEG-ADA at 4, 8, 16 kHz, <0.0001) (n=5 for each cohort).
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mice are given PEG-ADA shortly after for one week.

Intriguingly, we found that resumption of PEG-ADA treatment for two weeks
significantly lowered ABR threshold (Figure 13) but no significant effects on DPOAE thresholds
comparing to STOP-treatment Ada-/- mice (data not shown). This improvement of hearing
sensitivity by resumption of PEG-ADA therapy was accompanied by a mild increase in Peak I
amplitude at 8kHz (Figure 14) and a consistent decrease of latency at 8 and 16 kHz at higher
decibels (Figure 15). Thus, PEG-ADA treatment successfully rescue the SNHL in Ada-/- mice
with withdrawal of PEG-ADA therapy for 2 weeks largely by restoring the firing ability of SGN
and inter-peak transduction from SGN to CN but no obvious improvement in cochlear amplifier

Figure 13. ABR analysis on Ada-/- after PEG-ADA rescue
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Figure 14. Peak I and. II analysis on Ada-/- mice after PEG-ADA rescue therapy. (mean ± SEM)
Auditory brainstem response traces were analyzed, where Peak 1 amplitudes were elevated in
Rescue cohort compared to STOP-treatment mice. Peak II is similar to Peak I, indicating higher
capacity of neurons to fire effectively with lowered adenosine after onset of hearing loss at twoweeks PEG-ADA withdrawal (p-value, 8kHz peak I p-value for 90-80, 0.0436, 0.1708, 0.1813,
respectively) (p-value, 8kHz peak II p-value for 90-80, 0.6663, 0.6529, 0.6663, respectively) (pvalue, 16kHz peak I p-value for 90-80, 0.59643, 0.79332, 0.56095, respectively) (p-value, 16kHz
peak II p-value for 90-80, 0.9643,0.7634, 0.6783 , respectively) (n=5 for each group)
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Next, we conducted IF to determine whether PEG-ADA therapy is capable of restoring
the impaired myelination and prevent the fiber loss of SGN in Ada-/- mice with withdrawal of
PEG-ADA therapy for 2 weeks. Strikingly, we found that that PEG-ADA therapy induced
improved integration of MPZ to the myelin sheaths and restored nerve fibers (Figure 16). Taken
together, we demonstrated that PEG-ADA therapy restores the integration of MPZ to myelin
sheaths, reverses the loss of nerve fiber of SGN, and rescues SNHL in Ada-/- mice.
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Figure 16. Nerve fiber and MPZ protein immunofluorescent staining on Ada-/- mice cochlear
nerve. MPZ staining of peripheral nerve fiber of SGN, showing no significance between the two
except for organization of structures. (G) (mean ± SEM) Quantification of total expression of
NF200 and MPZ over total axon area (p-value for NF200 and MPZ, 0.0134 and 0.397343,
respectively) (n=3 for each group) Data are shown as mean ± SEM
2.4 Discussion
Extracellular adenosine is a signaling metabolite that orchestrates a physiological and
pathological response to energy deficiency or cell injury by functioning via one or more of the
four adenosine receptors. The pathogenic role of elevated adenosine in SNHL associated with
ADA-deficiency (33,34) in humans is confirmed and validated in Ada-/- mice (35). Defining the
pathogenic mechanism of SNHL in ADA-deficient humans is difficult for ethical and
experimental reasons. Although ADA deficiency is a lethal condition in humans and mice, PEGADA enzyme therapy, a treatment that substantially reduces (but does not eliminate) the
accumulation of adenosine, successfully prolongs life indefinitely. Thus, we took full advantage
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of our genetic model of adenosine-induced SNHL in Ada-/- mice and our ability to experimentally
regulate cochlear adenosine levels by administration of PEG-ADA to determine the natural
progression and molecular basis underlying SNHL in Ada-/- mice, which is impossible to study in
Ada-/- patients. First, we found that Ada-/- mice begin to develop bilateral SNHL after 7 days and
up to 14 days after stopping PEG-ADA treatment. Second, continuous ADA enzyme therapy
normalizes the cochlear adenosine levels and prevents SNHL in Ada-/- mice. Third, Ada-/- mice
display a minor loss of OHCs, severe unmyelinated myelin sheaths with impaired MPZ
integration and thus SNHL. Fourth, we provide a clear window of therapeutic opportunity for
PEG-ADA treatment for SNHL by revealing that PEG-ADA therapy reverses impaired MPZ
integration to myelin sheaths, restores myelinated nerve fiber of SGNs and rescues SNHL of Ada/-

mice following a two-week STOP-treatment with PEG-ADA. Thus, our findings add a

significant new insight that elevated cochlear adenosine as a signaling metabolite rapidly
promotes SNHL within 7 days, while PEG-ADA enzyme therapy can effectively prevent and
quickly reverse SNHL by improving myelination of nerve fibers of SGNs in Ada-/- mice. Overall,
our finding, not only provide substantial new insight regarding the cellular and metabolic basis
underlying natural progression of prolonged elevated adenosine-induced SNHL in Ada-/- mice,
but also provide a clear window of therapeutic opportunity for PEG-ADA treatment for SNHL in
these mice.
Elevated cochlear adenosine perturbs spiral ganglion neuron myelination
Here, we have characterized how elevated cochlear adenosine affects the hearing process,
from a physiological to a cellular perspective. We conclude that elevated cochlear adenosine
causes hearing loss mainly through perturbing proper myelination in the inner ear. We know this
because of the mild hair cell losses we find in untreated Ada-/- mice and the rescue capabilities of
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reintroducing PEG-ADA therapy after two weeks of withdrawal when we observe the hearing
loss.
To our knowledge, there are no current studies that show the direct role of adenosine in
peripheral myelination. Given our one-week resumption of PEG-ADA in our rescue experiment,
we hypothesize that, during this period, normalizing adenosine levels were enhancing axonal
structure and myelin organization. Without proper nerve fiber structures, auditory processing
from mechanical transduction of the middle ear ossicles and hair cells will simply not transmit to
higher brain regions. In this study, we focused on the cochlear VII nerve and cochlear nucleus
amplitude and latency where we saw blatant changes when adenosine is high or lowered with
PEG-ADA. While many cellular drivers could be responsible for this phenomenon we narrowed
it to two: a change in SGN number or perturbation in how the auditory information is transmitted.
When we found that SGN cell body count did not change with adenosine levels, we then looked
at the axons.
Adenosine levels play a role in MPZ function and expression
Axons play an important role in transmitting electrical impulses and most axon function
and structure are maintained through myelin escheatment. Many studies have shown the important
role of adenosine in myelination in the CNS (65), however, adenosine-regulated maintenance of
axonal structure remains to be determined. We found differences in NF-200 and MPZ expression
when adenosine levels were manipulated through PEG-ADA therapy. In elevated cochlear
adenosine, MPZ levels were elevated while nerve fiber structures were decreased. MPZ is the
most abundant peripheral myelin protein expressed and integrated in Schwann cell plasma
membranes that primarily keeps myelin properly coiled via in trans homophilic adhesion in its
extracellular domain (63,66–68). Clinical studies have shown the that MPZ dosage is important
for its proper function, where increased overexpression in peripheral nerves show
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hypomyelination neuropathy and axon-sorting defects and heterozygous and complete MPZ
knockouts in mice both present neuropathic phenotypes of progressive demyelination or
dysmyelination (69–72). Studies have also posited the possibility of detecting levels of MPZ in
cerebrospinal fluid (CSF) to determine the degree of demyelination in neuropathies (73). Taken
together, it would not be surprising to find increasing expression of MPZ in stress-induced
cochlear environment matched with increasing levels of adenosine.
As previously mentioned, environmental stress, such as acoustic trauma, can induce
elevated levels of adenosine. Studies in other tissues have found that elevated adenosine also
stimulates increased levels of ectonucleotidase CD73; thus, metabolizing more ATP and
increasing adenosine level. In our mouse model, extracellular adenosine metabolism is inhibited,
exacerbating the extracellular environment with the accumulation of adenosine levels that may
induce downstream pathogenic signaling. The exact downstream mechanism as to how sustained
elevated adenosine can prompt demyelination remains unknown and will be further discussed in
the next chapter.
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CHAPTER 3: Hearing Loss via ADORA2B Signaling
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3.1 Introduction
The previous chapters highlighted the characterization of how elevated adenosine affects
sensorineural hearing on a cellular level and a therapeutic perspective. This chapter will discuss
how adenosine a2b receptor is a potential downstream signaling pathway that leads to hearing
loss. In this study, we used a specific ADORA2B receptor inhibitor, PSB1115, and a total knockout Adora2b in the Ada mouse model. We found that ADORA2B ablation improved overall
hearing sensitivity and myelination in these models.
3.3 Materials & Methods
Ada-/- Mice and PSB1115 prevention regimen
Ada-/- mice were generated and genotyped as previously reported (50). Mice homozygous
for the null Ada allele were labeled Ada-/-, while mice genotyped with the Ada allele were labeled
as Adawt. All mice were congenic on a C57BL/6 background, and all phenotypic comparisons
were performed among littermates. PSB1115 was generated from water-soluble, HPLC grade,
powder from Tocris Bioscience diluted with sterile 1x DPBS (200 ug/per day). Ada-/- mice were
raised with PEG-ADA as described above from birth to 8 weeks. PSB1115 was injected
intraperitoneally every other day for two weeks.
Ada-/-/Adora2b-/- mice
Ada-/-/Adora2b-/- mice were generated by mating Ada-/- mice with Adora2b-/-. Ada-//

Adora2b-/- mice were raised with PEG-ADA as described above from birth to 8 weeks. All mice

were congenic on a C57BL/6 background, and all phenotypic comparisons were performed
among littermates.
RT-PCR
Total RNA was isolated from mouse whole DRG or DRG culture for 48h by using TRIzol
reagent (Invitrogen, Carlsbad, CA, USA). RNase-free DNase (Invitrogen) was used to eliminate
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genomic DNA contamination. Transcript levels were quantified using SYBR green reporter dye.
Primer sequences for ADORA1, ADORA2A, ADORA2B, and ADORA3 expression analysis
were referenced from previous work (27,28,74). GAPDH was used as endogenous control for
normalization.
Cochlea isolation, immunohistochemistry, imaging, and analysis
Temporal bones were dissected in PBS, incubated in 4% paraformaldehyde (PFA) in PBS
overnight at 4°C, decalcified in 0.2 M EDTA for 5–7 d. Fixed tissue were embedded in OCT
compound, cryosectioned at 10 um, followed by standard immunohistochemistry procedure. The
tissue sections were washed with 1x phosphate-buffered saline (PBS), followed by a 1 hr
incubation in 5% BSA with 1% Triton X-100 in 1xPBS. These sections were then incubated in
primary antibodies overnight at 4°C. The primary antibodies used for this study were: nerve fiber
filament (mouse anti-NF-200, Sigma, 1:200), neuron cell bodies (rabbit anti-NeuN, Abcam,
1:500), and myelin protein zero (rabbit anti-MPZ, Abcam 1:200). Tissues were then incubated
with appropriate Alexa-Fluor conjugated secondary antibodies (Invitrogen, 1:500), followed by
DAPI mountant (ProLong Gold Antifade, Thermo Fisher Scientific).
Confocal z-stacks of each cochlea were taken using Zeiss LSM T-PMT microscope
equipped with 63x (2x digital zoom) oil immersion lens. MPZ- and NF-200 areas were quantified
using ImageJ by selecting via consistent color threshold for each antibody used across all
experiment groups (n=3 each) and normalizing each sample by total area of the axon. These
MPZ+/total axon area and NF200+/total axon quantifications were collectively compared across
all experiments via a Mann-Whitney nonparametric two-tailed t-test. All statistical analyses were
performed via Prism 8.
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Auditory brainstem response recording
Mice were intraperitoneally injected with ketamine-xylazine (100 mg/kg: 10mg/kg).
Testing was performed in a soundproof faraday cage booth while mice were placed on heating
pad to maintain normal body temperature throughout the procedure. Pure tone bursts (0.1 ms
rise/fall, 2 ms duration, 21 presentations/s) from 4 to 48 kHz were generated using System 3
digital signal processing hardware and software (Tucker Davis Technologies). The intensity of
the tone stimuli was calibrated using a type 4938 one-quarter inch pressure-field calibration
microphone (Bru¨el & Kjær). EC1 ultrasonic, low-distortion electrostatic speakers were coupled
to the ear canal to deliver stimuli within 3 mm of the tympanic membrane. Response signals were
recorded with subcutaneous needle electrodes inserted at the vertex of the scalp (channel 1), the
postauricular bulla region (reference), and the back leg (ground), and averaged over 500
presentations of the tone bursts (56). Electrode-recorded activity was filtered (high pass, 300 Hz;
low pass, 3kHz; notch, 60Hz) before averaging to minimize background noise. Auditory
thresholds were determined by decreasing the sound intensity of each stimulus to 10 dB from 90
dB in 5 dB steps until the lowest sound intensity with reproducible and recognizable waveforms
was detected. Thresholds were determined to within 5 dB for each frequency by two raters to
ensure reliability. SD (dB SPL) were plotted as a function of stimulus frequency (kilohertz) and
analyzed for group differences by a two-way ANOVA, followed by a multiple-comparison test,
to reveal overall trends. Prism 8 was used for all statistical analyses.

ABR waveform detection and calculation
Peak amplitudes (I and II) were visually determined from ABR waves detected from each
stimulus from 90 to 10 dB in 5 dB increments at each frequency. Peak amplitudes were measured
by subtracting the peak voltage from the trough voltage at every dB presentation, averaged per
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experimental group. All averaged peak amplitudes for each peak from each group were
statistically compared using two-way ANOVA, followed by a multiple comparison test.
Peak latencies from peak I and II were calculated by subtracting Peak I’s peak amplitude
temporal onset (in ms) from Peak II’s peak amplitude temporal time onset (in ms). Time
measurements were averaged per experimental group. Averaged latencies per group were
compared via two-way ANOVA, followed by a multiple comparison test.
All statistical analyses were performed through Prism 8.

Distortion product otoacoustic emission measurements
DPOAEs were measured from a probe tip microphone placed in the external canal of the
mouse ear that were elicited by two 1-second sine-wave tones of varying frequencies
(F2=1.2*F1). F2 had a varied range of frequencies from 4 to 90 kHz. These two tones were
presented in identical intensities that ranged from 15 to 75 dB SPL in 15 dB increments. The
magnitude of the 2*F1-F2 DP was determined by FFT. DPOAE thresholds (>-5 dB SPL and
greater than two std. dev above noise floor) were analyzed off-line via BioSigRZ program. If no
DPOAE was detected, we defined the threshold to be at 75 dB, as our equipment is limited to 80
dB SPL. DPOAE thresholds were averaged per experimental group and compared via one-way
ANOVA, followed by a multiple comparisons test. All statistical analyses were done through
Prism 8.
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3.3 Results
Cochlear Adora2b expression
To determine which adenosine receptor is responsible for the decrease in wave peak
amplitudes and axonal structure changes in elevated cochlear adenosine-induced hearing loss, we
performed an RT-PCR analysis for four adenosine receptors in STOP- and PEG-ADA-treated
mice. We found that Adora2b mRNA was preferentially and significantly induced compared with
PEG-ADA treated Ada-/- and WT (C57B6-J) mice (Figure 17). Given the fact that ADORA2B
has the lowest affinity to adenosine and it is frequently activated under pathological conditions
with an excess level of adenosine (31,75), we immediately hypothesized that elevated ADORA2B
in the cochlea functions as a malicious cycle to promote elevated cochlear adenosine-induced
SNHL in Ada-/- mice. To test this possibility, we conducted preclinical studies to see whether
inhibition of ADORA2B activation by its specific inhibitor, PSB1115, can serve as a potential
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Figure 17. Adenosine receptors mRNA expression in Ada-/whole cochlea. RT-PCR of Adora2b gene with highest
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Figure 18. PSB1115 therapy on Ada-/- mice. Schematic diagram of PSB1115 therapy where
STOP-treatment mice are compared with mice treated with PSB1115 treatment.
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PSB1115-treated Ada-/- Auditory Brainstem Response and Distortion Product Otoacoustic
Emissions Analyses
Indeed, we found significant improvements in ABR thresholds (Figure 19, left) and mild
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improvements in DPOAE thresholds (Figure 19, middle and right).
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Figure 19. Auditory brainstem response and distortion product otoacoustic emission analysis on
Ada-/- mice with PSB1115. (left) After one week of PSB1115 therapy in Ada-/- mice auditory
brainstem response (ABR) thresholds at different frequencies demonstrate a rescued hearing
phenotype (p-value for 4-16 kHz, 0.2960, <0.0001, <0.0001, respectively) (n=5 for each cohort).
(middle and right) (mean ± SEM) Distortion-product otoacoustic emissions (DPOAEs) measured
at 8 and 16 kHz demonstrate improved outer hair cell and cochlear amplifier function in PSB1115treated mice compared to STOP treatment mice (p-value, 0.0286) (n=4 for each cohort).

SGNàCN Amplitude Peaks & Latency in PSB1115-treated Ada-/Moreover, at 8 and 16 kHz, peak 1 and 2 ABR amplitudes and latencies improved
substantially (Figure 20-21). Similar to PEG-ADA therapy, we found that PSB1115 treatment
significantly improved integration of MPZ to myelin sheaths and prevented nerve fiber loss of
SGN (Figure. 4G). Overall, these data support our hypothesis that ADORA2B activation mediated
by elevated cochlear adenosine plays an essential role in nerve fiber deterioration, which in turn,
affects hearing sensitivity in Ada-/- mice.
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Figure 20. Peak I and II analysis on Ada-/- mice after PSB1115 therapy. (mean ± SEM) Auditory
brainstem response traces were analyzed, where Peak 1 amplitudes were elevated in PSB1115treated cohort compared to STOP-treatment mice. Peak II is similar to Peak I, indicating higher
capacity of neurons to fire effectively inhibition of ADORA2B despite high adenosine levels (pvalue for 8kHz peak I, 90-80dB, 0.04973, 0.00486, 0.07595, respectively) (p-value for 8kHz peak
II, 90-80dB, 0.0265 0.0400 0.0316, respectively) (p-value for 16kHz peak I, 90-80dB, <0.0001 )
(p-value for 16kHz peak II, 90-80dB, 0.02547, 0.01265, 0.01077 , respectively) (n=5 per group)
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Figure 21. Peak I-II latency analysis on Ada-/- mice
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ADORA2B-inhibition in Elevated Cochlear Adenosine and Axon Structures
Similar to PEG-ADA therapy, we found that PSB1115 treatment significantly improved
integration of MPZ to myelin sheaths and prevented nerve fiber loss of SGN (Figure 22). Overall,
these data support our hypothesis that ADORA2B activation mediated by elevated cochlear
adenosine plays an essential role in nerve fiber deterioration, which in turn, affects hearing
sensitivity in Ada-/- mice.
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Figure 22. Nerve fiber and MPZ protein immunofluorescent staining on Ada-/- mice with PSB1115
therapy cochlear nerve. MPZ and NF200 staining is less and improved in organizational pattern
in PSB1115 treated mice with elevated adenosine compared to STOP-treatment mice with
elevated adenosine (p-value, left panel, 0.1732, middle panel, 0.0192, right panel, <0.0001)(n=3
per group) Data are shown as mean ± SEM.

Ada-/-/Adora 2b-/- Auditory Brainstem Response and Distortion Product Otoacoustic Emissions
Analyses
Similar to our PEG-ADA and PSB1115-treated Ada-/- mice, genetic deletion of Adora2b
in Ada-/- mice have improved hearing thresholds through ABR analyses (Figure 24). These
double-deficient mice were raised similar to Ada-/- mice with a PEG-ADA therapy from birth for
normal development (Figure 23). Despite adenosine increase upon PEG-ADA withdrawal,
hearing sensitivity was conserved. Although these decrease in threshold shifts are not as robust as
PSB1115 therapy on Ada-/- mice, these results further demonstrate ADORA2B’s role in hearing
loss pathogenesis through both ABR and DPOAE analyses (Figure 24).
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Figure 23. Ada-/-/Adora2b-/- mouse model. These double-deficient mice undergo normal
development through the same PEG-ADA therapy regimen that was given to Ada-/- mice.
However, after 8 weeks, PEG-ADA is withdrawn to allow the natural accumulation of adenosine
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Figure 24. Auditory brainstem response and distortion product otoacoustic emission analysis on
Ada-/-/Adora2b-/- mice. (left) After two weeks of PEG-ADA withdrawal in Ada-/-/Adora2b-/- mice
auditory brainstem response (ABR) thresholds at lower frequencies demonstrate a improved
hearing phenotype compared with STOP-treatment Ada-/- mice (p-value for 4-16 kHz, 0.0063,
0.0109, 0.0218, respectively) (n=4 for each cohort). (middle and right) (mean ± SEM) Distortionproduct otoacoustic emissions (DPOAEs) measured at 8 and 16 kHz demonstrate improved outer
hair cell and cochlear amplifier function in PSB1115-treated mice compared to STOP treatment
mice (p-value for 8 and 16 kHz, <0.0001 and >0.0003, respectively) (n=4 for each cohort).
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SGNàCN Amplitude Peaks & Latency in Ada-/-/Adora2b-/As we looked closely at the ABR traces, we found that at 8 and 16 kHz, peak 1 and 2 ABR
amplitudes and latencies improved substantially in Ada-/-/Adora2b-/- mice compared to STOPtreatment mice (Figure 25). Additionally, Ada-/-/Adora2b-/- mice were observed to have a faster
latency than STOP-treatment mice (Figure 26). Overall, these physiological ABR and DPOAE
data further support our hypothesis that ADORA2B activation mediated by elevated cochlear
adenosine plays an essential role in hearing loss pathogenesis.
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Figure 25. Peak I and II analysis on Ada-/-/ Adora2b-/- mice compared to STOP treatment Ada-/mice. (mean ± SEM) Auditory brainstem response traces were analyzed, where Peak I and II
amplitudes at 8 kHz were elevated in Ada-/-/ Adora2b-/- cohort compared to STOP-treatment mice
despite elevated systemic adenosine in both groups. At 16 kHz, however, only Peak II had a
significant increase in Ada-/-/ Adora2b-/- cohort compared to STOP-treatment mice (p-value for
8kHz peak I, 90-80dB, 0.0030, 0.0283. 0.0438, respectively) (p-value for 8 kHz peak II, 90-80dB
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is >0.0001) (p-value for 16 kHz peak I, 90-80dB, <0.0001) (p-value for 16 kHz peak II, 90-80dB
is >0.0001) (n=4 per group)
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3.4 Discussion
Although an unexpected bilateral SNHL was reported in humans with ADA-deficiency,
the molecular basis underlying SNHL in ADA-deficient humans remains undefined. Here, we
demonstrate that Ada-/- mice mimicking ADA-deficient humans display bilateral SNHL with
severe hypomyelination of SGNs. Intriguingly, PEG-ADA therapy reverses the hypomyelination
of SGNs and rescues SNHL in Ada-/- mice. Mechanistically, elevated cochlear adenosine
preferentially induces Adora2b gene expression and that enhanced ADORA2B signaling
functioning as a malicious cycle to further exacerbate SNHL in Ada-/- mice. Preclinically, blocking
ADOAR2B activation improves myelination and hearing sensitivity in Ada-/- mice. This is also
validated by our Ada-/-/Adora2b-/- model that showed the same physiological improvements.
Significantly, ADAOR2B is a detrimental purinergic signaling component underlying
hypomyelination of SGN and promoting aging-dependent SNHL, one of the common causes of
SNHL. Overall, our studies revealed that ADORA2B is a common pathogenic factor impairing
myelination in two independent models of SNHL and immediately highlights novel adenosinebased therapies for SNHL.

ADORA2B as a common pathogenic factor underlies hypomyelination in both Ada-/- mice and
aging-dependent SNHL
Adenosine is perhaps best known for its role as a major signal transducer in response to
hypoxia or tissue injury (76). Adenosine is a signaling nucleoside that elicits its effect on target
cells by engaging four specific G-protein coupled receptors ADORA1 and ADORA3 receptors
are coupled to adenylyl cyclase by the inhibitory G-protein (Gαi) and hence serve to lower
intracellular levels of the second messenger cAMP. The ADORA2A and ADORA2B receptors
are commonly coupled to adenylyl cyclase by the stimulatory G-protein (Gαs) and serve to
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increase intracellular cAMP. Adenosine signaling plays important roles in regulating homeostasis
in a number of physiological and pathological systems including the cardiovascular, nervous,
renal and immune systems. On one hand, acute and transient elevation of adenosine protects
tissues from hypoxia-ischemic-mediated damage by promoting vasodilation, O2 delivery and antiinflammation (75). On another hand, persistent accumulation of adenosine signaling via
ADORA2B functions to promote or exacerbate tissue injury and disease progression including
priapism, preeclampsia, chronic kidney disease, hypertension, pulmonary fibrosis , chronic pain,
and sickle cell disease (26–32). However, functional role of ADOAR2B in SNHL is unrecognized
prior to our study presented here. Previous histological studies have shown the specific cellular
expression in the cochlea of all adenosine receptors but one, ADORA2B (9,46), which it is not
surprise since ADOAR2B antibody is not well accepted in the field for either immunostaining or
even Western blot analysis. Consistent with early studies that Adora2b expression is induced in
chronic disease states, particularly in sustained adenosine levels (26–32), we found that Adora2b
mRNA is increased with elevated adenosine levels after PEG-ADA withdrawal for 2 weeks in
Ada-/- mice. Pharmacologically inhibiting ADORA2B improves cochlear nerve fiber by
increasing MPZ integrating to myelin sheaths and thus attenuates SNHL in Ada-/- mice. Prompted
by the detrimental role of ADORA2B signaling-mediated impaired myelination in Ada-/- mice,
we further demonstrated that genetic deletion of ADOAR2B promotes integration of MPZ to
myelin sheaths, protects nerve fiber and thus slows down the progression of SNHL induced by
elevate adenosine. Thus, both preclinical and genetic studies point to the detrimental role of
ADOR2B in another chronic disease condition, SNHL, and pave a way for receptor-based specific
therapies for the disease.
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ADORA2B impairs MPZ integration to myelin sheaths in peripheral nervous system
Schwann cells are the only cell type that express MPZ, a major promyelinating protein
driving remyelination and responsible for myelin compaction in the peripheral nervous system
(PNS). Previous studies have shown importance of MPZ in several neuropathies, such as Charcot
Marie Tooth Disease (CMT) (61). CMT patients have disrupted Schwann cell and peripheral
nerve axons, as well as bilateral “hidden” HL similar to ADA-deficient patients (77). If MPZ is
not properly integrated into myelin sheaths, it may be secreted from Schwann cells as a soluble
molecule. Thus, the soluble MPZ level in cerebral spinal fluid is used to determine the severity
of a neuropathy in the clinic (61). Additionally, previous studies point to the aberrant effects of
elevated MPZ expression, indicating the importance of myelin compaction in axonal integrity
(63,78). It is important to note that MPZ requires a critical dosage for proper myelin function,
otherwise, it leads to hypomyelination (63,68). How MPZ expression is finely regulated and
properly assembled to myelin sheaths remains poorly understood. To our surprise, we found that
MPZ is elevated and disorganized expression throughout the whole nerve bundle of SGN in Ada/-

mice. However, pharmacologically interfering ADORA2B attenuates elevated MPZ expression,

restoring MPZ integrating to myelin sheaths and maintain myelination of nerve fibers of SGN in
these mice. Similarly, genetic deletion of ADORA2B improves MPZ assembling to myelin
sheaths. Thus, our findings revealed that ADORA2B is a common pathogenic receptor impairing
integration of MPZ to myelin sheaths, inducing hypomyelinated nerve fibers of SGNs and thus
promoting SNHL. Notably, early studies showed that acute exposure of adenosine promotes
myelination by inducing oligodendrocyte progenitor cells differentiation to myelinated
oligodendrocytes in the central nervous system (CNS) (65). Thus, it is very important to define
how persistently elevated adenosine signals via ADORA2B and regulates myelination mediated
by oligodendrocyte in CNS.
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Novelty and Therapeutics for SNHL
In conclusion, SNHL is a challenging condition. However, specific means to prevent or
treat SNHL are limited due to a lack of understanding of the underlying mechanisms. Our
discovery about elevated adenosine signaling via ADORA2B-mediated demyelination of
peripheral SGNs in Ada-/- mice has provided molecular insight to SNHL in ADA-deficient
patients. Extending from Ada-/- mice, the discovery of pathogenic role of ADORA2B in aginginduced SNHL is also highly innovative. Overall, our studies revealed that ADORA2B is a
common pathogenic factor impairing myelination in two independent models of SNHL and
immediately highlights novel adenosine-based therapies for SNHL. In this way our findings
reveal important novel opportunities to treat and prevent SNHL by targeting adenosine signaling
and ADORA2B-mediated effects. Moreover, our findings immediately suggest that reducing
adenosine-ADORA2B-mediated demyelination of SGNs are likely innovative therapeutic
possibilities to treat and prevent progression of SNHL by improving myelination in SGNs.
Altogether, our findings provide us better understanding of the molecular basis underlying SNHL
and highlight multiple therapeutic strategies to treat SNHL and to prevent the progression to
becoming debilitating.
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CHAPTER 4: Other HL Models and Future Directions
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4.1 Introduction
Sensorineural hearing loss is a very broad and common disability that does not have a
definitive known cause; however, we believe that exploring another model apart from Ada-/- will
give us a better understanding on what drives this irreversible sensory damage. We decided to
look at the most common type of sensorineural hearing loss, presbycusis, or age-related hearing
loss. This chapter will discuss how ADORA2B-mediated adenosine signaling plays a role in aging
mice on a functional and cellular level. Indeed, we found that hair cell dysfunction and
demyelination can be prevented by Adora2b deletion in aging mice. In addition to our aging
model, we explored how ADORA2B might play a role in sickle-cell disease, a disease with
elevated systemic adenosine and hearing-loss incidence. Finally, this chapter will highlight
potential therapies and discuss future directions for studying elevated cochlear adenosine in
sensorineural hearing loss.
4.2 Materials and Methods
Adora2b-deficient Aging Mice
For aging studies, we compared Adora2b-/- mice that are 1.5 years old with age-matched
C57BL/6. Adora2b-/- mice were generated in our laboratory that were initially transferred from
Dr. Michael Blackburn’s laboratory. 6-month old C57B6J mice were generously provided by Dr.
Louise McCullough and Dr. Claudio Soto’s labs. All studies were reviewed and approved by the
University of Texas Health Science Center at Houston Animal Welfare Committee.
PSB1115-therapy of Aging Mice
PSB1115 was generated from water-soluble, HPLC grade, powder from Tocris Bioscience
diluted with sterile 1x DPBS (200 ug/per day). We treated 6-month old C57BL/6 mice with
PSB1115 and measured ABR days after.
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Sickle-Cell Disease Mice
Berkeley SCD transgenic mice were purchased from The Jackson Laboratory. Bone
marrow transplantation (BMT) was achieved in Adora2b-/- mice by collecting and purifying bone
marrow from SCD transgenic mice donor and transplanted into irradiated and previously fed 0.2
% neomycin for one day Adora2b-/- mice retro-orbitally under isoflurane anesthesia. SCD-A2B
mice were fed with 0.2% neomycine sulfate water for two weeks after transplantation and are
monitored for two weeks.

Cochlea isolation, immunohistochemistry, imaging, and analysis
Temporal bones were dissected in PBS, incubated in 4% paraformaldehyde (PFA) in PBS
overnight at 4°C, decalcified in 0.2 M EDTA for 5–7 d. Fixed tissue was embedded in OCT
compound, cryosectioned at 10 µm, followed by standard immunohistochemistry procedure. The
tissue sections were washed with 1x phosphate-buffered saline (PBS), followed by a 1 hr
incubation in 5% BSA with 1% Triton X-100 in 1xPBS. These sections were then incubated in
primary antibodies overnight at 4°C. The primary antibodies used for this study were: nerve fiber
filament (mouse anti-NF-200, Sigma, 1:200), neuron cell bodies (rabbit anti-NeuN, Abcam,
1:500), and myelin protein zero (rabbit anti-MPZ, Abcam 1:200). Tissues were incubated with
appropriate Alexa-Fluor conjugated secondary antibodies (Invitrogen, 1:500), followed by DAPI
mountant (ProLong Gold Antifade, Thermo Fisher Scientific).
Confocal z-stacks of each cochlea were taken using Zeiss LSM T-PMT microscope
equipped with 63x (2x digital zoom) oil immersion lens. MPZ- and NF-200 areas were quantified
using ImageJ by selecting via consistent color threshold for each antibody used across all
experiment groups (n=3 each) and normalizing each sample by total area of the axon. These
MPZ+/total axon area and NF200+/total axon quantifications were collectively compared across
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all experiments via a Mann-Whitney nonparametric two-tailed t-test. All statistical analyses were
performed via Prism 8.

Auditory brainstem response recording
Mice were intraperitoneally injected with ketamine-xylazine (100 mg/kg: 10mg/kg).
Testing was performed in a soundproof faraday cage booth while mice were placed on heating
pad to maintain normal body temperature throughout the procedure. Pure tone bursts (0.1 ms
rise/fall, 2 ms duration, 21 presentations/s) from 4 to 48 kHz were generated using System 3
digital signal processing hardware and software (Tucker Davis Technologies). The intensity of
the tone stimuli was calibrated using a type 4938 one-quarter inch pressure-field calibration
microphone (Bru¨el & Kjær). EC1 ultrasonic, low-distortion electrostatic speakers were coupled
to the ear canal to deliver stimuli within 3 mm of the tympanic membrane. Response signals were
recorded with subcutaneous needle electrodes inserted at the vertex of the scalp (channel 1), the
postauricular bulla region (reference), and the back leg (ground), and averaged over 500
presentations of the tone bursts (56). Electrode-recorded activity was filtered (high pass, 300 Hz;
low pass, 3kHz; notch, 60Hz) before averaging to minimize background noise. Auditory
thresholds were determined by decreasing sound intensity of each stimulus to 10 dB from 90 dB
in 5 dB steps until the lowest sound intensity with reproducible and recognizable waveforms was
detected. Thresholds were determined to within 5 dB for each frequency by two raters to ensure
reliability. SD (dB SPL) were plotted as a function of stimulus frequency (kilohertz) and analyzed
for group differences by a two-way ANOVA, followed by a multiple-comparison test, to reveal
overall trends. Prism 8 was used for all statistical analyses.
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ABR waveform detection and calculation
Peak amplitudes (I and II) were visually determined from ABR waves detected from each
stimulus from 90 to 10 dB in 5 dB increments at each frequency. Peak amplitudes were measured
by subtracting the peak voltage from the trough voltage at every dB presentation, averaged per
experimental group. All averaged peak amplitudes for each peak from each group were
statistically compared using two-way ANOVA, followed by a multiple comparison test.
Peak latencies from peak I and II were calculated by subtracting Peak I’s peak amplitude
temporal onset (in ms) from Peak II’s peak amplitude temporal time onset (in ms). Time
measurements were averaged per experimental group. Averaged latencies per group were
compared via two-way ANOVA, followed by a multiple comparison test.
All statistical analyses were performed through Prism 8.

Distortion product otoacoustic emission measurements
DPOAEs were measured from a probe tip microphone placed in the external canal of the
mouse ear that were elicited by two 1-second sine-wave tones of varying frequencies
(F2=1.2*F1). F2 had a varied range of frequencies from 4 to 90 kHz. These two tones were
presented in identical intensities that ranged from 15 to 75 dB SPL in 15 dB increments. The
magnitude of the 2*F1-F2 DP was determined by FFT. DPOAE thresholds (>-5 dB SPL and
greater than two std. dev above noise floor) were analyzed off-line via BioSigRZ program. If no
DPOAE was detected, we defined the threshold to be at 75 dB, as our equipment is limited to 80
dB SPL. DPOAE thresholds were averaged per experimental group and compared via one-way
ANOVA, followed by a multiple comparisons test. All statistical analyses were done through
Prism 8.
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4.2 Results
Adora2b-deficient Aging Mice and Hearing Loss
Previous studies have shown that presbycusis in aging mice is associated with increased
thresholds, latencies and decreased amplitudes in early waves (Peak I of cochlear nerve and lower
brainstem nuclei) (79), which is similar to the phenotype of SNHL seen in Ada-/- mice. Thus, we
extended from our Ada-/- mice to determine if ADORA2B signaling plays a role in age-dependentSNHL. It is known that C57B6J mice (WT) begin to decrease hearing sensitivity after 6 months
of age and progress to SNHL at 1 year old (79–81). Thus, we tested if ADORA2B ablation would
also improve hearing sensitivity in aging mice. We compared hearing sensitivity by measuring
ABR thresholds of Adora2b-/- mice and WT mice at 6 months (young) and at 1 year (aged),
respectively.
Similar to Ada-/- mice treated with ADORA2B inhibitor (Figure 19), we found that aged
Adora2b-/- mice conserved lower ABR thresholds compared to aged WT, while no difference of
ABR thresholds between Adora2b-/- mice and WT mice at 6-month old young age (Figure 27).

Figure 27. ABR analysis of aged WT mice and aged
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Distortion Product Otoacoustic Emissions of Aging Mouse Models
As expected, aged mice did not have functional mechanical transduction. DPOAE analysis
between aged WT and aged Adora2b-/- mice revealed that both groups had 75 dB as thresholds
for both 8 and 16 kHz (data not shown). Previous studies have shown that C57B6J mice have
progressive increase of auditory thresholds due to hair cell and spiral ganglion cell degeneration
(82). Age-related hearing loss is posited to be largely due to OHC loss beginning as early as 2
months of age in these mice (82). Interestingly, hearing sensitivity can be preserved despite loss
of OHC electromotile properties. Hair cell loss during aging, especially in C57B6 mice, has been
posited to be independent of SGN loss during the aging process(83). The exact mechanisms for
this matter remain to be studied.
SGNà CN Amplitude Peaks & Latency in Aging Mouse Models
The lack of DPOAE signals indicate age-related changes in OHC function; however, we
still found differences in ABR thresholds between WT and Adora2b-/- aged mice. ABR thresholds
only indicate hearing sensitivity on neuronal transduction levels in regions after SGN stimulation.
We wanted to delineate further how ADORA2B may play a role in the hearing process. Indeed,
we found that ABR peak I and II amplitudes and latencies in 8 and 16 kHz of Adora2b-/- aged
mice were also significantly higher than WT, indicating preserved SGN firing capacity (Figure
28) and no neuronal transduction delay (Figure 29). Thus, we provide genetic evidence that
ADORA2B is a pathogenic receptor for aging-induced SNHL.
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Figure 28. Peak I and II analysis of
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PSB1115 therapy on Aging WT Mice
We have shown that ADORA2B is a receptor that could play a role in age-related hearing
loss pathogenesis genetically; however, whole knock-out deletions in mice has their limitations.
Therefore, we tested if the effects of ADORA2B inhibitor, PSB1115, will present the same
attenuating effects on aging mice. C57B6J are known to have severe hearing loss by 9-month old
and threshold shifts after 6 therefore, we wanted to test whether these mice will have improved
hearing sensitivity before they have complete hearing loss at >1-year-old if we blocked
ADORA2B pharmacologically at 6-months of age (79–81) (Figure 30). Indeed, we found that
PSB1115-treated WT mice at 6 months have improved ABR after one day of treatment (Figure
31, left). Additionally, we observed a steady day-by-day increase of ABR thresholds after
PSB1115 treatment on these 6-month old WT mice(Figure 31, right). DPOAE thresholds were
also improved but limited to 16 kHz (Figure 32). However, no overt differences were observed in
ABR peaks 1 & 2 at 8 and 16 kHz (data not shown). ABR thresholds are often an indication of
summated auditory response starting at higher dB; however, when peak amplitudes do not reflect
ABR threshold shifts, differences in firing capacity may not be as robustly different at higher dBs
despite the decreased firing capacity differences at lower dBs where the thresholds are
determined. These data are in parallel with the rescued hearing phenotypes of aging mice with the
genetic ablation of Adora2b and suggest that this receptor plays a role in aging associated with
adenosine.
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Figure 30. PSB1115 therapy on 6-month-old C57B6J mice. 6-month-old C57B6J mice are treated
with PSB1115 to see how an ADORA2B inhibitor will affect normal hearing in younger mice
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PSB1115 therapy (p-value between PSB111-treated WT and untreated WT for 8 kHz is 0.0342)
(n=4).
Structural and potential molecular mechanisms in Aging Models
Aging in mice inevitably loosens and unravels myelin sheaths with eventual
demyelination(84). This often leads to the lack of protection of nerve fiber filaments, which we
observed in our aged WT mice (Figure 27). In view of the detrimental role of ADORA2B in the
demyelination of SGN in Ada-/- mice (Figure 10) and given the similar improvement of hearing
sensitivity in aged Adora2b-/- mice and ADORA2B inhibitor treated Ada-/- mice, we hypothesize
that ADORA2B is a previously unrecognized molecule responsible for demyelination seen in
aging-induced SNHL. Similar to PSB1115 treated Ada-/- mice (Figure 22), we found that aged
Adora2b-/- mice conserved nerve fiber (Figure 33). These findings provide genetic evidence that
ADORA2B is detrimental to cause demyelination in aging-induced SNHL.
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Figure 33. Nerve fiber and MPZ protein immunofluorescent staining on aged Adora2b-/- cochlear
nerve compared to aged WT. Spiral ganglion neurons stained with dapi. MPZ and NF200 staining
is increased and improved in organizational pattern in Adora2b-/- aged mice compared to WT aged
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mice (p-value, left panel, 0.0003, right panel, <0.0001) (n=3 per group) Data are shown as mean
± SEM.
Aging in mice also affects morphologic and functional elements of the myelin sheaths of
peripheral nervous system (PNS) with the decrease of MPZ expression(85–87). Decreased MPZ
expression in aging contributes to loosening and unraveling of myelin sheaths as it is an integral
membrane protein that maintains the multilamellar structure of myelin sheaths (64). Given the
discovery of ADORA2B in impaired compact of MPZ to myelin sheaths in Ada-/- mice, we tested
the possible role of ADORA2B in MPZ compaction in myelin sheaths in aging-induced SNHL.
Similar to PSB1115 treated Ada-/- mice, Adora2b-/- mice showed a significant improvement of
MPZ expression in myelin sheaths compared to aged WT mice (Figure 33), suggesting
detrimental role of Adora2b in myelin sheath organization in aging-induced SNHL and in ADAdeficiency-induced SNHL. Taken together, we conclude that genetic deletion of ADORA2B
markedly attenuates impairment of MPZ integrating to myelin sheaths and demyelination of
cochlear nerve fibers and thus improves sensory hearing ability during aging.
On a pharmacological level, 6-month-old WT mice ABR thresholds improved after 1-day
treatment of ADORA2B antagonist, PSB1115. This is a remarkably fast response; therefore, we
posit that ADORA2B-specific inhibition is producing a response on a metabolic level. One
possibility is ADORA2B’s role in the regulation of metabolites in the Organ of Corti. Within the
Organ of Corti, ATP is periodically released from supporting cells that lead to eventual potassium
release (88). This culmination of potassium then leads to depolarization of inner hair cells that
lead to glutamate release that will activate SGNs (88). The hearing process requires a balance in
glutamate release, otherwise it will be excitotoxic. ADORA2B could play a role in any of these
fast-acting responses, such as the vesicular release of glutamate. Cochlear excitotoxic
mechanisms are still unknown; however, it is known that glutamate is concentrated in synaptic
vesicular transporter, vesicular glutamate transporter type 3 (Vglut3) (89). To date, the role of
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ADORA2B in VGLUT3’s function is unknown. Overall, we can only conclude that ADORA2B
inhibition via PSB1115 has a fast-acting response to threshold shifts. This is useful information
for future studies, especially in a therapeutic setting. Whether PSB1115 can be used as a treatment
to temporary hearing loss or prevent age-related hearing loss remains to be elucidated.

Possible Molecular Pathogenesis in SNHL Associated with Elevated Adenosine
It is no surprise that purinergic signaling is a pathway explored in earlier works of SNHL.
The hearing process demands an abundance of ATP and HL is often attributed to a disruption in
this metabolic energy currency. While we do not provide evidence of an intricate molecular
pathway for the pathogenesis of SNHL, we have narrowed down a potential signaling pathway
that can be targeted therapeutically.
Our research is built on substantial data generated from Ada-deficient mice that display
bilateral sensorineural HL mimicking ADA-deficient humans. Additionally, we use the same
FDA-drug (PEG-ADA) ADA-deficient patients use to lower systemic adenosine and monitor how
adenosine progression contributes to HL. This pharmacological approach revealed a correlation
between adenosine progression and gradual HL, as we have shown with the steady increase of
ABR threshold. More importantly, we found that this pathogenesis to be reversible within a
specific time-frame of adenosine accumulation. Further studies are required to understand how
elevated adenosine signaling play a role in myelination in the inner ear. Given that myelin has
high lipid content, any disruption of Schwann cell mitochondria where purinergic signaling is
perturbed can lead to dysfunction in fatty acid metabolism.
Our metabolomics profiling revealed that these untreated mice have abnormally high
levels of long-chain acylcarnitines (LCA) and succinate (Figure 34), metabolites involved in
mitochondrial functions, such as the carnitine-shuttle system and the TCA cycle. ATP is generated
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via transport of activated long-chain fatty acids from the cytoplasm to the mitochondria through
carnitine-shuttle

system

(90,91).

On

the

outer

mitochondrial

membrane,

carnitine

palymitoyltransferase I (CPT1) transesterifies CoA moiety for carnitine which yields in LCAs
(90,91). LCAs are transported through the mitochondrial matrix where they are metabolized back
into free-carnitine and acyl-CoA by carnitine palymitoyltransferase II (CPT2) in the inner
mitochondrial membrane(90). Acyl-CoA subsequently undergoes beta-oxidation to provide
energy for high-ATP demand tissues (90,92). Studies have shown that CPT2-deficiency leads to
mitochondria-generated oxidative stress that lead to energy-deficiency and cell death (93,94).
CPT2’s relationship with adenosine and HL, however, is unknown. Our preliminary data suggests
that chronic elevation of adenosine results in detrimental accumulation of LCAs.
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Figure 34. Mitochondrial fatty acid metabolism pathways and related metabolomics profile of
PEG-ADA treated and untreated Ada-/- mice. (left) Schematic diagram of carnitine-shuttling
system, a process required for long-chain fatty acids to enter the mitochondria for metabolism and
overall energy production. (right) PEG-ADA withdrawal results in elevated cochlear long-chain
acylcarnitines and succinate in Ada-/- mice. Metabolomics profiling reveal cochlear long-chain
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acylcarnitines and succinate levels were significantly increased in Ada-/- mice following
withdrawal of PEG-ADA therapy (n=6). Data are shown as mean ± SEM.

Myelin sheaths contain 70% of lipid and 30% of proteins, where the most abundant protein
is MPZ that holds the sheaths together in PNS (61). Previous studies have shown that aberrant
Schwann cell lipid metabolism is linked to mitochondrial dysfunction that lead to axon
degeneration and neuropathy (95). In this study, they showed elevated palmitoylcarnitines that
correlated with elevated axon degeneration, which parallels our metabolomic study and decreased
expression of NF-200 in elevated cochlear adenosine (95). Our cochlear metabolomics profile
reveals

the

highest

significant

accumulation

of

palmitoylcarnitine,

in

particular.

Palmitoylcarnitines facilitate transfer of long-chain fatty acids through the mitochondrial
membranes for beta-oxidation to generate ATP. The continuous release of ATP to be hydrolyzed
into adenosine presents a cyclic pathology and elevated levels of long-chain acyl-carnitines can
alter membrane fluidity through hydrophobic bonds with lipids and membrane proteins.
Alternatively, previous studies have shown that hypoxia can induce elevated levels of long-chain
acyl-carnitines, and from our lab’s previous work, we know that hypoxia is associated with
sustained levels of adenosine (96–99). Moreover, multiple early studies have shown elevated
adenosine plays a role in lipid metabolism (100–102). However, whether and how ADORA2B
disturbs lipid metabolism, leading to decreased lipid integrity, releasing soluble MPZ,
hypomyelination or axon degeneration and progression of SNHL remain elusive.
To our knowledge, there are no studies that link ADORA2B signaling with acylcarnitine
accumulation, however, one possible pathway could be due to ADORA2B’s capability to induce
PKA signaling. Our lab has previously found that elevated adenosine levels activate ADORA2B
that induces PKA phosphorylation, followed by proteasomal degradation of a protein necessary
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for cellular homeostasis(103). ADORA2B-mediated proteasomal degradation may play a role in
in

decreasing

CPT2

levels,

resulting

in

long-chain

acylcarnitine

accumulation.

Palmitoylcarnitines, in particular, have been found to inhibit PKC, an important protein for MPZ
phosphorylation that allows it to be adhesive for myelin compaction (104,105). Overall, we posit
that ADORA2B disturbs lipid integrity in myelin compaction, leading to demyelination, axonal
damage, and decreased hearing sensitivity (Figure 35).

Figure 35. Working Model.
Chronically elevated cochlear
adenosine causes hearing loss via
preferentially

amplified

ADORA2B signaling, increasing
levels of palmitoylcarnitines that
disrupt myelin compaction via
disruption of membrane fluidity
and MPZ function, leading to
demyelination

and

axon

degeneration, and overall leading
to sensorineural hearing loss
(SNHL) in Ada-/- mice. Lowering
adenosine
inhibiting
ADORA2B

(PEG-ADA)

or

(PSB1115)
improves

and

prevents SNHL by attenuating nerve fiber and MPZ structure that are otherwise damaged in Ada/-

mice. Genetic deletion of ADORA2B improves MPZ integrating to myelin sheaths, attenuates

demyelination and slows down the progression of SNHL in aging. Thus, ADORA2B is a common
pathogenic factor underlying SNHL in both Ada-/- mice and aged WT mice and an innovative
therapeutic target. Downstream targets like CPT2 with bezafibrate could be a potential therapeutic
regimen for hearing loss to decrease palmitoylcarnitines that inhibit PKC activity for MPZ
phosphorylation that retain their adhesion properties, overall composing the myelin integrity.
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Other Disease Models: Sickle-Cell Disease and Hearing Loss
Bilateral hearing loss is the most common hearing loss complication in sickle-cell disease
(SCD) patients, however, little is known of its pathophysiology. Interestingly, SCD patients and
rodent models have elevated systemic adenosine (31,101,106–111). Our lab has found that SCD
patients and mouse models have elevated circulating adenosine that lead to various multi-organ
damages, such as pain and priapism (31,111)(101). Pain and priapism pathophysiology studies in
SCD transgenic mice were attributed to ADORA2B-mediated signaling from sustained systemic
adenosine levels(26,31). With prior knowledge of purinergic signaling playing a role in hearing
loss, it was reasonable to test hearing capacities in SCD transgenic mice.
The Berkeley SCD transgenic mouse is a widely accepted SCD model that expresses the
human sickle hemoglobin exclusively, and we found that WT mice with bone marrow transplants
(BMT) from SCD mice phenocopy hearing loss from SCD patients. SCD-WT mice nearly have
complete hearing loss at higher dBs; however, when SCD BMT was conducted in either CD73-/or Adora2b-/- mice (SCD-CD73-/- & SCD-Adora2b-/-, respectively), this hearing loss is improved
(Figure 36). At 8 and 16 kHz, SCD-CD73-/- mice have significantly lowered ABR thresholds
compared to SCD-WT, while SCD-Adora2-/- was only significantly lower at 8kHz. As previously
mentioned in Chapter 1, CD73 is an ectonucleosidase that metabolizes AMP into adenosine,
therefore, SCD-CD73-/- theoretically lowers adenosine systemically while SCD-Adora2b-/- have
high adenosine levels without global ADORA2B signaling stimulation. Here, we concluded that,
similar to PEG-ADA and ADORA2B ablation, lowering adenosine or inhibiting ADORA2B
activation improves or prevents hearing loss.
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Figure 36. ABR analysis of sickle-cell transplanted -WT,

SCD-Adora2b-/-

SCD-WT
SCD-CD73-/-

C57B6J mice, indicating CD73 and Adora2b ablation
improves hearing in SCD.

Interestingly, OHC functionality in SCD-CD73-/- and SCD-Adora2b-/- only had lowered
thresholds in 16 kHz compared to SCD-WT, while thresholds at 8 kHz in all three groups were
similarly low (Figure 37). This may be an indication that SCD-WT may have outer hair cell
damage at the apex of the cochlea, where stimulation at 16 kHz is more sensitive. Sickle-cell
anemia can cause vaso-occlusive crisis (VOCs), leading to ischemia in the labyrinthine artery in
the inner ear(112). Hypoxia in the inner ear can lead to outer hair cell death, an irreversible
damage; however, lacking CD73 or ADORA2B seem to prevent this possible hearing loss onset
in SCD mouse models.
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Figure 37. DPOAE analysis of sickle-cell
SCD-WT
SCD-CD73-/SCD-Adora2b-/n.s.
n.s.
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transplanted -WT, CD73-/-, and Adora2b-/-.
Berkeley SCD bone marrow transplanted in
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CD73-/- and Adora2b-/- mice show decreased
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DPOAE thresholds compared to SCD bone

marrow transplanted C57B6J mice, indicating CD73 and Adora2b ablation improves outer hair
cell functionality at 16 kHz in SCD. DPOAE thresholds at 8 kHz show no difference between
three groups. (at 16 kHz, p-value between SCD-WT and SCD-CD73-/- is 0.0128 and p-value
between SCD-WT and SCD-Adora2b-/- is 0.0128 ) (n=5).
70

As we looked closer in our SCD mice ABR traces, we found the same trend that only 16
kHz frequency revealed statistically significant differences between 3 groups. While peaks I and
II (cochlear VIII nerve and cochlear nucleus, respectively) amplitudes at 8 kHz did not reveal
significant changes in all three groups (data not shown), both revealed the same trend of having
lowered amplitude at higher dBs in SCD-WT compared with transplanted CD73-/- or Adora2b-/-,
suggesting a lower capacity for hearing and sending electrical transduction to higher brain regions.
16 kHz, on the other hand, revealed that ablation of CD73 or Adora2b can improve this process
(Figure 38). Whether outer hair cells that respond to 16 kHz frequency is directly correlated with
this process remains to be determined; however, we do know that SGN type II synapse with basal
OHC and only account for 5% of the ganglion cells, while type I SGNs synapse with IHCs, and
both types directly innervate to the cochlear nuclei. Latency analyses of peak I to II reveal that
both frequencies do not have any statistically significant changes in temporal neuronal activity
transmission (data not shown).
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Figure 38. Peak I and II analysis of sickle-cell transplanted -WT, CD73-/-, and Adora2b-/-. (mean
± SEM) Auditory brainstem response traces were analyzed, where Peak 1 amplitudes were
elevated in Berkeley SCD bone marrow transplanted in CD73-/- and Adora2b-/- mice compared to
SCD bone marrow transplanted C57B6J mice in 16 kHz Peak I at higher dB (cochlear VII nerve).
While only transplanted CD73-/- cohort have elevated peak II amplitudes (cochlear nucleus)
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compared to transplanted WT mice. (Peak I SCD-WT vs SCD-CD73-/- p-value for 90 dB is
0.0014. While SCD-WT vs SCD-Adora2b-/- p-value is 0.0007. Peak I SCD-WT vs SCD-CD73-/p-value for 90, 85, and 80 dB is <0.0001, 0.4507, and 0.0211, respectively) (n=3 per group)
Overall, we show that the SCD mouse model parallels SCD patient hearing loss
phenotypes. To our knowledge, these findings have yet to be published in literature. While several
studies have published incidences of hearing loss in SCD patients across the world, deeper
molecular studies in patients or animal models have yet to be investigated. Previous studies have
shown higher frequency hearing loss in SCD patients and suggest that this may be due to the
nature of the cochlea having terminal arteries(108,109). SCD patients, in general, experience
VOCs due to the stickiness of the sickled red blood cells, which can ultimately perturb blood flow.
Cochlear labyrinthine blood vessels are susceptible to labyrinthine hemorrhage and labyrinthitis
ossificans and may be caused by VOCs but remains to lack incidence support in the clinic
(113,114). Any further molecular studies also remain to be investigated.
Our study broadly explores the potential role of adenosine signaling in SCD and many
other plausible causes can be explored in SNHL onset in SCD patients. Other SCD pathologic
changes, such as infection and chronic hemolytic anemia, are other branches of study that can be
explored in sensorineural hearing loss which adenosine signaling has been associated with in other
SCD studies (26,101). Another consideration in studying SNHL in SCD is how its etiology may
differ among SCD patients with varying ß-globin chain abnormality (HbSS, HbSC, HbS/ßthalassemia). Current methodologies, audiology screenings on SCD patients in different age
groups, are still limited, and therapeutic options for hearing loss have yet to be discovered.
Therefore, it is imperative to further investigate and explore correlations between SCD, SNHL,
and adenosine.

72

4.4 Future Directions
1) What is the cellular and metabolic basis underlying the natural progression of elevated
adenosine-induced HL in Ada-/- mice?
Our metabolomics profiling, pharmacological tools, and cellular and genetics techniques
provide substantial data on our Ada-/- HL model. HL is often attributed to hair cell and neuronal
cell losses in the cochlea; however, our cochleogram and immunofluoresence staining of SGN
bodies analyses did not present significant hair cell and SGN loss, respectively, in STOPtreatment Ada-/- mice. Instead, we found increasing demyelination as adenosine accumulates post
PEG-ADA treatment. Conservation of hair cells was also validated via DPOAE analysis, where
we found mild differences in DPOAE thresholds between PEG-ADA treated and stop-treatment
Ada-/- mice. Additionally, our preliminary data show elevated adenosine increase cochlear
succinate levels, indicating a disruption of the TCA cycle via succinate dehydrogenase (SDH).
SDH has been found to be involved in multiple disease conditions (115–118), including
ototoxicity and aging cochlea (119,120). SDH is also a part of the mitochondrial electron transport
chain (ETC) that contributes to ATP production. Indeed, we also found an accumulation of
cochlear long-chain acylcarnitines (LCA) in Ada-/- mice with eleveated adenosine and as
previously mentioned, a disruption in mitochodnrial function has been shown to disrupt axon
degeneration and neuropathy. However, a deeper molecular understanding in this HL model is
still missing.
i)

Cochlear Schwann Cell profiling – The limitations of our finding lie on the fact that
pharmacological therapies were applied on a systemic level while investigating a
complex multi-cellular sensory organ.It would be interetsing to investigate whether
demyelination is caused by a perturbation in TCA cycle metabolism in Schwann cells.
While metabolomic profiling is sophisticated way to dilineate molecular pathways,
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our results relfect metabolism in the whole cochlear system under different adenosine
levels. Metabolic profiling of isolated Schwann cell from PEG-ADA treated and
STOP-treatment Ada-/- mice would be most ideal to see how sustained adenosine levels
play a role in fatty acid metabolism in Scwhann Cell. Alternatively, establishing and
observing Schwann cell cultures under increasing adenosine levels would be
interesting. Previous studies have shown that adenosine promotes differentiation and
myelination in the CNS (65), however ATP does the opposite in the PNS (65). This
finding supports our hypothesis of the detrimental cyclic behavior of sustained
elevated adenosine, where ATP is continuously released extracellularly under stressful
environments, such as hypoxia and acoustic overstimulation, consequently increasing
adenosine levels via increased CD73 expression and function. To our knowledge,
adenosine’s direct affect on Schwann cell differentiation or myelination remains to be
investigated. Therefore, determining whether elevated adenosine can directly increase
MPZ expression and palmitoylcarnitines would be imperative.
ii)

TCA Cylcle and Acylcarnitine Metabolism – While specifying the cell type
responsible for a sustained-adenosine neuropathy that leads to senosrineural hearing
loss is important, the goal is to always delineate a mechanism that can contribute to a
molecular-based therapy. As previously mentioned, accumulation of long-chain
acylcarnitines disrupts overall ATP generation and can potentially contribute to
membrane potential equilibrium through changes in membrane fluidity (96–98). It
would be interesting to see if sustained adenosine levels indeed disrupt fatty acid
metabolism by testing for decreased CPT2 activity or expression levels, and how it
correlates with overall ATP levels. Other acylcarnitine metabolism enzyme functions
should also be considered, such as CPT1, since it is responsible for the
transesterification of coA for carnitine. However, CPT1 is not known to be expressed
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in mitochondria of neurons in the central nervous system (90,93). It would also be
interesting to see if changing adenosine levels affects SDH expression and function
and determine whether this is the cause of a perturbation in TCA cycle leading to
accumulation of succinate.
iii)

Specific inner-ear approach – To mimic elevated adenosine levels outside of a rare
genetic disorder that is Ada-deficiency, introduction of high adenosine levels in wildtype C57BL/6J mice using 2'-Deoxycoformycin (DCF) to block ADA can reveal how
chronic elevated levels of adenosine underlie HL. To determine whether sustained
adenosine levels truly affect inner ear physiology, 2'-Deoxycoformycin (DCF)-soaked
gelatin sponge (Gelfoam) application in the round window membrane can directly
block ADA in C57BL/6J inner ear. This will allow us to monitor if we can recapitulate
elevated cochlear adenosine pathology on a metabolic, cellular, and physiological
levels.

iv)

Direct CPT2 rescue therapy - Using the same hydrogel technique, directly increasing
Cpt2 expression in the inner ear via virus vector-mediated gene therapy in both
untreated Ada-/- mice and DCF-treated C57BL/6J mice can reveal whether chronic
adenosine-mediated sensorineural hearing loss disrupts fatty acid metabolism or not.
Alternatively, a direct increase of Cpt2 expression and function in the inner ear via
bezafibrate therapy in both untreated Ada-/- mice and DCF-treated C57BL/6J mice
could be used to test changes in hearing sensitivity. Bezafibrate is an FDA-approved
drug used to increase CPT2 expression and function, however, whether CPT2deficient patients have sensorineural hearing loss remains to be evaluated.

v)

PEG-ADA rescue therapy – We have shown that PEG-ADA resumption can reverse
hearing loss after a 2-week PEG-ADA withdrawal for adenosine accumulation. While
we showed that this could improve hearing sensitivity, axon integrity, and MPZ
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compaction, we have yet to show that it affects myelin integration. We also did not
show whether metabolic profiling, palmitoylcarnitine levels in particular, was reversed
to normal levels after PEG-ADA resumption; therefore, CPT2 expression or function
should also be determined. Further EM analysis on these cochleae to see whether
myelin compaction is back normal would also be imperative.
vi)

Adenosine-mediated hearing loss in SCD and aging models – Although we determined
that these models, indeed, have hearing loss that parallel with clinical findings, we
have yet to determine whether they have elevated cochlear adenosine. HPLC analysis
in different age groups (young, middle-aged, and aged) of the aging model are needed
to test whether presbycusis is correlated with increasing adenosine levels over time.
Although systemic adensoine was found in SCD patients and mouse models, cochlear
adenosine is yet to be determiend compared to control models. Further inner ear
cellular experiments, such as cochleograms and EM, would be pertitent to determine
whether adenosine-mediated demyelination is a pathway applicable to all types of
sensorineural

hearing

loss

incidences.

Additionally,

therapeutic

models

aforementioned would also be an exciting scientific venture. PEG-ADA and
bezafibrate are FDA-approved drugs that might have minimal side-effects that can be
used to see if loss of hearing sensivity can be reversed or prevented through a
reasonable regimen application.
vii)

Other alternative strategies – Consideration of loss of other cell types (endothelial,
stria cells, etc) and testing for stria vascularis and blood-labyrinth barrier integrity via
Evan’s blue staining is imperative (56,121–123). Overall, if these models do not
represent the relationship of HL and adenosine accumulation, one can invest in noiseinduced HL mice models where noise-exposed rodents have shown to have elevated
ATP and have been posited to have elevated adenosine (3,4,9,124). This HL model
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can be used to investigate whether lowering adenosine levels with PEG-ADA therapy
can ameliorate HL in noise-exposed rodents.
2) What is ADORA2B’s role in the cellular and metabolic disturbance in HL in Ada-/- mice?
Our RT-PCR profiling confirmed Adora2b to be expressed the most in stoptreatment Ada-/- mice compared to WT and PEG-ADA treated Ada-/- mice. We found that
Ada-/- mice with PEG-ADA withdrawal, treated with ADORA2B antagonist (PSB1115),
displayed a significant hearing improvement compared with stop-treatment mice. On a
genetic level, Adora2b-deficient Ada-/- mice (Ada-/-/Adora2b-/-) have improved hearing
compared to PEG-ADA treated and untreated Ada-/- mice. Overall, we have shown that
ADORA2B signaling ablation under elevated and sustained adenosine conditions can
ameliorate SNHL in Ada-/- mice. We augmented this finding by extending how
ADORA2B signaling can affect presbycusis in aging and SCD mouse models, further
validating the receptors role in SNHL. Opportunities to explore ADORA2B signaling in
chronic cochlear adenosine levels can be achieved by applying techniques mentioned in
the previous section. However, much is to be investigated downstream of ADORA2B in
other models.
i) ADORA2B and Adenosine levels – Although we have shown that blocking or
genetically deleting ADORA2B is beneficial in ameliorating hearing loss under
chronic levels of adenosine, adenosine HPLC analyses and metabolomic profiling
were not performed in these models. To date, there are no evidences that
ADORA2B signaling affects adenosine levels, however, it is an imperative piece
of information to delineate whether ADOR2B is activating pathologic downstream
mechanisms or simply lowering adenosine levels. Metabolomic profiling in
models that we have used will also shed light into whether acylcarnitines are
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decreased under these circumstances that lead to better myelination and hearing
loss.
ii) ADORA2B signaling in SCD and aging models - ADORA2B is known to be
elevated in chronic disease states, particularly in sustained adenosine levels (26–
32). Moreover, ADORA2B has the least affinity to adenosine and is, therefore,
dependent on sustained accumulation of extracellular adenosine for activation.
ADORA2B has been shown to be expressed in rodent cochlea, however, increased
cochlear Adora2b expression is yet to be determined models we have used. A
simple RT-PCR or western blot of whole cochlea could determine Adora2b
expression in SCD and aged WT mice; however, specific Adora2b expression
changes from isolated Schwann cells from these models would be most idea.
Alternatively, a simple co-immunofluorescent staining of any Schwann cell
marker (MPZ, myelin basic protein, etc) and ADORA2B antibody in cochlea
sections would be ideal. Unfortunately, to this day, adenosine signaling experts
have yet to find a good ADORA2B antibody.
iii) PKA signaling – Our lab previously found that elevated adenosine activates
ADORA2B and induces PKA phosphorylation, followed by proteasomal
degradation of a protein necessary for cellular homeostasis (103). Additionally,
ADORA2B receptors couple to adenylyl cyclase via G-protein (Gαs) stimulation
and increase intracellular cAMP (125). Protein kinase A (PKA) is the first
identfied downstream target of cAMP (125). It would be interesting to investigate
whether cochlear PKA expression and phosphorylation is induced under elevated
adenosine levels and inhibited or diminished when ADORA2B is ablated. A
simple way to address this is to perform immunoflourescent staining on sectioned
cochlea with PKA-substrate antibodies in Ada-/- mice. Untreated Ada-/- mice
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should have elevated PKA-substrate expression post PEG-ADA withdrawal. PKAsubstrate expression, then, would be expected to diminish in Ada-/-/Adora2b-/- and
PSB111-treated Ada-/- mice. To determine whether PKA signaling induces the
protein degradation pathway, specifically targeting CPT2, immunoprecipitation
(IP) of ubiquitinated proteins and PKA substrates followed by western blot
analysis of CPT2 can be performed in either whole cochlea or isolated Schwann
cells in various of models mentioned above. CPT2 western blot expression should
decrease in sustained adenosine conditions.
iv) Schwann cell-specific Adora2b deletion – In order to specify ADORA2B’s role in
chronic adenosine-mediated HL, experiments can be performed in Schwann cell
deletion of Adora2b in Adora2b-floxed mouse treated with 2ʹ-Deoxycoformycin
(DCF) via Gelfoam-soaked adenovirus vector carrying Cre-Mpz gene. The use of
Gelfoam is a safer way to locally deliver drugs into the inner ear, as opposed to
injection of drugs into the cochlea via the round window membrane.
v) Other alternative strategies – To further validate ADORA2B-mediated HL
pathway, a GelFoam-soaked ADORA2B agonist, BAY 60-6583, in the inner ear
of C57BL/6J mice would be expected to have the same cochlear pathologies and
HL. Alternatively, a regimented Gelfoam-soaked PSB1115 in aging inner ear
would be an interesting experiment to see whether ADORA2B inhibition can
prevent presbycusis. Additional investigation of receptor function and expression
of other adenosine receptors, such as ADORA1, which is known to be
neuroprotective, would also be interesting (9,11).
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